José Baselga
#23,764
Most Influential Person Now
Spanish oncologist
José Baselga's AcademicInfluence.com Rankings
José Baselgaphilosophy Degrees
Philosophy
#2144
World Rank
#3725
Historical Rank
Logic
#458
World Rank
#858
Historical Rank
Download Badge
Philosophy
José Baselga's Degrees
- Doctorate Medicine University of Barcelona
- PhD Medicine University of Barcelona
Why Is José Baselga Influential?
(Suggest an Edit or Addition)According to Wikipedia, Josep Baselga i Torres, known in Spanish as José Baselga , was a Spanish medical oncologist and researcher focused on the development of novel molecular targeted agents, with a special emphasis in breast cancer. Through his career he was associated with the Memorial Sloan Kettering Cancer Center, Vall d'Hebron Institute of Oncology, and the Massachusetts General Hospital in their hematology and oncology divisions. He led the development of the breast cancer treatment Herceptin, a monoclonal antibody, that targets the HER2 protein, which is impacted in aggressive breast cancers.
José Baselga's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. (2001) (10106)
- Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. (2005) (4911)
- Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. (2006) (4805)
- The landscape of somatic copy-number alteration across human cancers (2010) (3297)
- Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. (2003) (2937)
- Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis (2014) (2895)
- Trastuzumab emtansine for HER2-positive advanced breast cancer. (2012) (2725)
- mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. (2006) (2509)
- Mutational Landscape of Metastatic Cancer Revealed from Prospective Clinical Sequencing of 10,000 Patients (2017) (2165)
- Systematic identification of genomic markers of drug sensitivity in cancer cells (2012) (2134)
- Tumor mutational load predicts survival after immunotherapy across multiple cancer types (2019) (2120)
- Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. (2012) (2045)
- Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition (2013) (1854)
- Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. (2010) (1824)
- Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. (2012) (1765)
- Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. (2015) (1516)
- 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial (2007) (1499)
- Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. (2012) (1492)
- Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. (2008) (1410)
- Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. (1996) (1402)
- Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. (2015) (1386)
- The EGF receptor family as targets for cancer therapy (2000) (1372)
- OncoKB: A Precision Oncology Knowledge Base. (2017) (1317)
- Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. (2003) (1278)
- Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. (2007) (1178)
- Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial (2012) (1159)
- Sequence analysis of mutations and translocations across breast cancer subtypes (2012) (1133)
- Novel anticancer targets: revisiting ERBB2 and discovering ERBB3 (2009) (1111)
- Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. (1998) (1107)
- Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort (2010) (1096)
- Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. (1998) (1085)
- A view on drug resistance in cancer (2019) (932)
- Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. (2010) (924)
- ESR1 ligand binding domain mutations in hormone-resistant breast cancer (2013) (908)
- AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. (2011) (906)
- Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. (2013) (857)
- Adjuvant Pertuzumab and Trastuzumab in Early HER2‐Positive Breast Cancer (2017) (847)
- Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. (2002) (835)
- Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. (2001) (827)
- PKB/Akt mediates cell-cycle progression by phosphorylation of p27Kip1 at threonine 157 and modulation of its cellular localization (2002) (819)
- Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. (2007) (798)
- NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. (2008) (785)
- The Epidermal Growth Factor Receptor Pathway: A Model for Targeted Therapy (2006) (785)
- Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. (2000) (759)
- Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. (2007) (753)
- Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. (2015) (727)
- Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. (2005) (727)
- Epidermal growth factor receptor targeting in cancer. (2006) (706)
- Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. (2005) (674)
- 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial (2017) (656)
- De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 (2018) (639)
- Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. (2010) (634)
- Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. (2012) (632)
- CDK8 is a colorectal cancer oncogene that regulates β-catenin activity (2008) (630)
- Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. (2002) (629)
- Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. (2009) (622)
- Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. (2005) (618)
- Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. (2011) (618)
- Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. (2002) (581)
- TGF-β Receptor Inhibitors Target the CD44(high)/Id1(high) Glioma-Initiating Cell Population in Human Glioblastoma. (2010) (571)
- A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. (2003) (570)
- The EGFR as a target for anticancer therapy--focus on cetuximab. (2001) (559)
- Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. (2012) (535)
- TGF-beta increases glioma-initiating cell self-renewal through the induction of LIF in human glioblastoma. (2009) (522)
- Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. (2008) (520)
- Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. (1993) (516)
- Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. (2002) (516)
- Why the epidermal growth factor receptor? The rationale for cancer therapy. (2002) (502)
- HER kinase inhibition in patients with HER2- and HER3-mutant cancers (2018) (500)
- PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. (2012) (492)
- Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. (2008) (490)
- PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer (2011) (485)
- High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene. (2007) (480)
- Targeting Tyrosine Kinases in Cancer: The Second Wave (2006) (467)
- Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes. (2017) (460)
- Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†. (2014) (459)
- Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. (1993) (458)
- Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial. (2015) (456)
- 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial (2013) (449)
- Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. (1993) (444)
- MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer (2017) (442)
- Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer. (2016) (430)
- Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. (2005) (428)
- Convergent loss of PTEN leads to clinical resistance to a PI3Kα inhibitor (2014) (417)
- Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies. (2017) (412)
- Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity (2009) (411)
- Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anti-cancer activity: a randomised multinational controlled phase III trial (1998) (405)
- mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling. (2011) (403)
- Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort. (2014) (402)
- Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. (2005) (397)
- Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. (1998) (397)
- Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. (2017) (396)
- Dissecting the heterogeneity of triple-negative breast cancer. (2012) (393)
- Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. (2005) (392)
- Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis (2013) (391)
- Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer. (2012) (381)
- Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response. (2014) (379)
- Translating p53 into the clinic (2010) (367)
- Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. (2017) (366)
- Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. (2010) (356)
- Gefitinib — a novel targeted approach to treating cancer (2004) (354)
- De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. (2018) (353)
- Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. (2011) (353)
- A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds (2016) (352)
- The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. (2018) (348)
- Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical Trial. (2016) (343)
- Implementing Genome-Driven Oncology (2017) (341)
- European Code Against Cancer and scientific justification: third version (2003). (2003) (332)
- β-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer (2012) (332)
- USP15 stabilizes TGF-β receptor I and promotes oncogenesis through the activation of TGF-β signaling in glioblastoma (2012) (331)
- Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. (2017) (326)
- Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing (2017) (321)
- Vitamin C crosses the blood-brain barrier in the oxidized form through the glucose transporters. (1997) (317)
- Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial. (2016) (317)
- Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial. (2017) (316)
- PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor–positive breast cancer (2015) (313)
- Genome doubling shapes the evolution and prognosis of advanced cancers (2018) (311)
- Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. (1999) (309)
- Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. (2016) (309)
- The 8q24 cancer risk variant rs6983267 demonstrates long-range interaction with MYC in colorectal cancer (2009) (308)
- Combined Epidermal Growth Factor Receptor Targeting with the Tyrosine Kinase Inhibitor Gefitinib (ZD1839) and the Monoclonal Antibody Cetuximab (IMC-C225) (2004) (307)
- Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer. (2013) (305)
- Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. (2007) (300)
- Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. (2006) (300)
- Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion (2011) (298)
- mTORC1 Inhibition Is Required for Sensitivity to PI3K p110α Inhibitors in PIK3CA-Mutant Breast Cancer (2013) (298)
- Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments. (2001) (292)
- Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer. (2019) (289)
- BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors. (2011) (276)
- Mechanism of action of trastuzumab and scientific update. (2001) (276)
- Inhibition of Bruton tyrosine kinase in patients with severe COVID-19 (2020) (276)
- Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. (2014) (274)
- Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. (2004) (273)
- Loss of HER2 Amplification Following Trastuzumab-Based Neoadjuvant Systemic Therapy and Survival Outcomes (2009) (271)
- Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells. (1999) (268)
- Tyrosine kinase inhibitors: why does the current process of clinical development not apply to them? (2004) (261)
- Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis. (2012) (260)
- 4E-binding protein 1: a key molecular "funnel factor" in human cancer with clinical implications. (2007) (259)
- Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer. (2011) (258)
- Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer (2013) (255)
- Recurrent and functional regulatory mutations in breast cancer (2017) (249)
- AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas. (2015) (249)
- ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells. (2003) (247)
- Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. (2012) (246)
- TACE is required for the activation of the EGFR by TGF‐α in tumors (2003) (243)
- Mechanism of action of anti-HER2 monoclonal antibodies. (2001) (243)
- Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway. (2018) (239)
- Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: A phase III study of high dose radiation therapy with or without cetuximab. (2004) (237)
- Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence (2016) (236)
- Tumour lineage shapes BRCA-mediated phenotypes (2019) (235)
- Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists. (2017) (231)
- Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients (2011) (231)
- Vemurafenib for BRAF V600–Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study (2017) (230)
- Biosynthesis of tumorigenic HER2 C‐terminal fragments by alternative initiation of translation (2006) (230)
- RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer (2018) (229)
- Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. (2007) (229)
- Carboplatin‐based versus cisplatin‐based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma (1997) (221)
- p95HER-2 Predicts Worse Outcome in Patients with HER-2-Positive Breast Cancer (2006) (220)
- Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response. (1995) (218)
- Cancer therapy shapes the fitness landscape of clonal hematopoiesis (2020) (218)
- The Evolving War on Cancer (2011) (218)
- Accelerating Discovery of Functional Mutant Alleles in Cancer. (2018) (216)
- Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study. (2017) (215)
- Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer. (2006) (215)
- PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner. (1997) (206)
- AKT Inhibition in Solid Tumors With AKT1 Mutations. (2017) (206)
- Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2. (2016) (205)
- PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer. (2015) (204)
- Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study. (2018) (203)
- First-in-Human Dose Study of the Novel Transforming Growth Factor-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Patients with Advanced Cancer and Glioma (2014) (203)
- A Phase I, Multicenter, Open-Label, First-in-Human, Dose-Escalation Study of the Oral Smoothened Inhibitor Sonidegib (LDE225) in Patients with Advanced Solid Tumors (2014) (202)
- Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01). (2014) (202)
- 4E-Binding Protein 1, A Cell Signaling Hallmark in Breast Cancer that Correlates with Pathologic Grade and Prognosis (2007) (201)
- Lapatinib with trastuzumab for HER 2-positive early breast cancer ( NeoALTTO ) : a randomised , open-label , multicentre , phase 3 trial (2012) (201)
- Clinical trials of Herceptin(trastuzumab). (2001) (200)
- PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D (2017) (198)
- p95HER2 and breast cancer. (2011) (196)
- NH2-terminal Truncated HER-2 Protein but not Full-Length Receptor Is Associated with Nodal Metastasis in Human Breast Cancer (2002) (195)
- Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. (2008) (194)
- Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study (2014) (193)
- Formulary availability and regulatory barriers to accessibility of opioids for cancer pain in Europe: a report from the ESMO/EAPC Opioid Policy Initiative. (2010) (193)
- Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer. (2009) (192)
- Targeted therapies for breast cancer. (2011) (189)
- BRAF Inhibition in BRAFV600-Mutant Gliomas: Results From the VE-BASKET Study (2018) (188)
- Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ. (2015) (186)
- Phase I Pharmacokinetic and Pharmacodynamic Study of the First-in-Class Spliceosome Inhibitor E7107 in Patients with Advanced Solid Tumors (2013) (183)
- CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer. (2016) (182)
- A Multicenter Phase II Trial of ZD6474, a Vascular Endothelial Growth Factor Receptor-2 and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients with Previously Treated Metastatic Breast Cancer (2005) (182)
- Phosphorylated 4E binding protein 1: A hallmark of cell signaling that correlates with survival in ovarian cancer (2006) (182)
- Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer. (2010) (181)
- Molecular Features and Survival Outcomes of the Intrinsic Subtypes Within HER2-Positive Breast Cancer (2014) (181)
- Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum‐based therapies (2008) (181)
- The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2 (2008) (180)
- HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications. (1997) (179)
- Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA (2014) (179)
- A Naturally Occurring HER2 Carboxy-Terminal Fragment Promotes Mammary Tumor Growth and Metastasis (2009) (176)
- Herceptin® Alone or in Combination with Chemotherapy in the Treatment of HER2-Positive Metastatic Breast Cancer: Pivotal Trials (2001) (176)
- PDK1-SGK1 Signaling Sustains AKT-Independent mTORC1 Activation and Confers Resistance to PI3Kα Inhibition (2016) (172)
- Expression of the fructose transporter GLUT5 in human breast cancer. (1996) (172)
- Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS-ERK signaling. (2014) (170)
- Emerging targeted agents in metastatic breast cancer (2013) (169)
- Status of PI3K inhibition and biomarker development in cancer therapeutics. (2010) (167)
- Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group. (2000) (167)
- Dual mTORC1/2 and HER2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-HER2 Therapy (2012) (165)
- TACE is required for the activation of the EGFR by TGF-alpha in tumors. (2003) (164)
- Interleukin‐2 enhances the natural killer cell response to Herceptin‐coated Her2 / neu‐positive breast cancer cells (2001) (164)
- A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer. (2004) (161)
- A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy (2008) (161)
- Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer. (2012) (161)
- Clinical Benefit of Lapatinib-Based Therapy in Patients with Human Epidermal Growth Factor Receptor 2–Positive Breast Tumors Coexpressing the Truncated p95HER2 Receptor (2010) (159)
- Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors. (2006) (158)
- Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor–Positive Advanced Breast Cancer: A Phase 1b Clinical Trial (2019) (156)
- Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer. (1996) (156)
- Phase II Trial of Antiepidermal Growth Factor Receptor Antibody C225 in Patients with Advanced Renal Cell Carcinoma (2003) (156)
- NH(2)-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer. (2002) (155)
- ZD1839 ('Iressa') as an anticancer agent. (2000) (154)
- Feasibility and Tolerability of Sequential Doxorubicin/Paclitaxel Followed by Cyclophosphamide, Methotrexate, and Fluorouracil and Its Effects on Tumor Response as Preoperative Therapy (2005) (152)
- Targeting the microtubules in breast cancer beyond taxanes: the epothilones. (2007) (152)
- Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer. (1996) (152)
- Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors (2013) (150)
- Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors. (2014) (149)
- A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation (2018) (147)
- Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors (2019) (144)
- A role for a PDZ protein in the early secretory pathway for the targeting of proTGF-alpha to the cell surface. (1999) (144)
- Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study. (2013) (144)
- Management of breast cancer with targeted agents: importance of heterogenicity (2010) (143)
- Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine (2002) (142)
- An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumors (2015) (141)
- Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer (2016) (139)
- Reduction of cytosolic p27(Kip1) inhibits cancer cell motility, survival, and tumorigenicity. (2006) (138)
- CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer. (2010) (136)
- Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors (2012) (135)
- Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors. (2012) (135)
- Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma. (2006) (134)
- Somatic PIK3CA mutations as a driver of sporadic venous malformations (2016) (134)
- P-selectin is a nanotherapeutic delivery target in the tumor microenvironment (2016) (134)
- Focus on breast cancer. (2002) (132)
- Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma. (2003) (132)
- Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER. (2018) (132)
- Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trials. (2015) (131)
- Antagonism of EGFR and HER3 Enhances the Response to Inhibitors of the PI3K-Akt Pathway in Triple-Negative Breast Cancer (2014) (130)
- Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy (2014) (129)
- 18F-FDG PET/CT for Early Prediction of Response to Neoadjuvant Lapatinib, Trastuzumab, and Their Combination in HER2-Positive Breast Cancer: Results from Neo-ALTTO (2013) (128)
- Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer (2009) (126)
- mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer (2017) (125)
- Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth (2009) (124)
- Metalloprotease-dependent Protransforming Growth Factor-α Ectodomain Shedding in the Absence of Tumor Necrosis Factor-α-converting Enzyme* (2001) (122)
- Cetuximab monotherapy is active in patients (pts) with platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN): Results of a phase II study. (2004) (122)
- Treatment of HER2-overexpressing breast cancer. (2010) (119)
- Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for resectable high-risk breast cancer: feasibility and efficacy. (1999) (119)
- Prevalence of Clonal Hematopoiesis Mutations in Tumor-Only Clinical Genomic Profiling of Solid Tumors (2018) (118)
- Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors. (2012) (118)
- Capecitabine (Xeloda) in combination with oxaliplatin: a phase I, dose-escalation study in patients with advanced or metastatic solid tumors. (2002) (118)
- Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer. (2009) (117)
- Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy (2014) (117)
- A Phase I Pharmacokinetic and Pharmacodynamic Study of Dalotuzumab (MK-0646), an Anti-Insulin-like Growth Factor-1 Receptor Monoclonal Antibody, in Patients with Advanced Solid Tumors (2011) (116)
- Trastuzumab, a humanized anti-HER2 monoclonal antibody, for the treatment of breast cancer. (1999) (116)
- Abstract S3-3: First Results of the NeoALTTO Trial (BIG 01-06/EGF 106903): A Phase III, Randomized, Open Label, Neoadjuvant Study of Lapatinib, Trastuzumab, and Their Combination Plus Paclitaxel in Women with HER2-Positive Primary Breast Cancer (2010) (116)
- RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer. (2013) (115)
- Proteomic Identification of Desmoglein 2 and Activated Leukocyte Cell Adhesion Molecule as Substrates of ADAM17 and ADAM10 by Difference Gel Electrophoresis (2006) (115)
- A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors. (2017) (115)
- Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors. (2017) (114)
- First-in-human phase I study of the oral PI3K inhibitor BEZ235 in patients (pts) with advanced solid tumors. (2010) (113)
- A feasibility study of carboplatin with fixed dose of gemcitabine in "unfit" patients with advanced bladder cancer. (2001) (112)
- Growth regulation of human renal carcinoma cells: role of transforming growth factor alpha. (1992) (111)
- Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer. (2014) (111)
- Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study. (2010) (110)
- RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial (2017) (105)
- Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR+, HER2− advanced breast cancer: results from BOLERO-2 (2017) (103)
- Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2 (2014) (101)
- Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2. (2013) (101)
- Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane. (2012) (101)
- Utility of serum HER2 extracellular domain assessment in clinical decision making: pooled analysis of four trials of trastuzumab in metastatic breast cancer. (2009) (101)
- PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab. (2016) (100)
- Meta-analysis Results from the Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC) (2012) (99)
- Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders. (2015) (96)
- Unraveling resistance to trastuzumab (Herceptin): insulin-like growth factor-I receptor, a new suspect. (2001) (96)
- Phase I Safety, Pharmacokinetics, and Inhibition of Src Activity Study of Saracatinib in Patients with Solid Tumors (2010) (94)
- Health‐related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO‐2 trial (2013) (92)
- Abstract S6-01:PIK3CAstatus in circulating tumor DNA (ctDNA) predicts efficacy of buparlisib (BUP) plus fulvestrant (FULV) in postmenopausal women with endocrine-resistant HR+/HER2– advanced breast cancer (BC): First results from the randomized, phase III BELLE-2 trial: (2016) (92)
- Massively parallel sequencing of phyllodes tumours of the breast reveals actionable mutations, and TERT promoter hotspot mutations and TERT gene amplification as likely drivers of progression (2016) (90)
- Results of a phase II trial of trastuzumab (H) and pertuzumab (P) in patients (pts) with HER2-positive metastatic breast cancer (MBC) who had progressed during trastuzumab therapy (2008) (90)
- Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer. (2016) (90)
- The epidermal growth factor receptor as a target for therapy in breast carcinoma (2004) (90)
- Microsatellite instability due to hMLH1 deficiency is associated with increased cytotoxicity to irinotecan in human colorectal cancer cell lines (2008) (89)
- Pro-Tumor Necrosis Factor-α Processing Activity Is Tightly Controlled by a Component That Does Not Affect Notch Processing* (1998) (89)
- Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer (2014) (89)
- Analysis of the 10q11 Cancer Risk Locus Implicates MSMB and NCOA4 in Human Prostate Tumorigenesis (2010) (89)
- TARGETING THE MUC1-C ONCOPROTEIN DOWNREGULATES HER2 ACTIVATION AND ABROGATES TRASTUZUMAB RESISTANCE IN BREAST CANCER CELLS (2013) (89)
- Receptor blockade with monoclomal antibodies as anti-cancer therapy (1994) (88)
- ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer (2020) (87)
- Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839. (2001) (87)
- Targeting the epidermal growth factor receptor: a clinical reality. (2001) (87)
- Clinical trial design and end points for epidermal growth factor receptor-targeted therapies: implications for drug development and practice. (2003) (87)
- Next-Generation Assessment of Human Epidermal Growth Factor Receptor 2 (ERBB2) Amplification Status: Clinical Validation in the Context of a Hybrid Capture-Based, Comprehensive Solid Tumor Genomic Profiling Assay. (2017) (87)
- A Phase II Pharmacodynamic Study of Erlotinib in Patients with Advanced Non–Small Cell Lung Cancer Previously Treated with Platinum-Based Chemotherapy (2008) (86)
- Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study. (2010) (86)
- Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2. (2013) (85)
- Biomarkers Predict p53 Gene Therapy Efficacy in Recurrent Squamous Cell Carcinoma of the Head and Neck (2009) (84)
- Tumour-specific PI3K inhibition via nanoparticle-targeted delivery in head and neck squamous cell carcinoma (2017) (83)
- Determinants of RASistance to anti-epidermal growth factor receptor agents. (2008) (83)
- Phase I pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor, in patients with advanced solid tumors. (2011) (83)
- Deconstructing feedback-signaling networks to improve anticancer therapy with mTORC1 inhibitors (2008) (83)
- Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245409 (XL765), a Novel, Orally Administered PI3K/mTOR Inhibitor in Patients with Advanced Solid Tumors (2014) (82)
- Selective inhibition of HDAC3 targets synthetic vulnerabilities and activates immune surveillance in lymphoma (2019) (82)
- Novel targeted therapies in the treatment of gastric and esophageal cancer. (2005) (82)
- NVP-BEZ 235 , a Dual PI 3 K / mTOR Inhibitor , Prevents PI 3 K Signaling and Inhibits the Growth of Cancer Cells with Activating PI 3 K Mutations (2008) (82)
- Phase I and II clinical trials of trastuzumab. (2001) (82)
- PIK3CA Genotype and a PIK3CA Mutation-Related Gene Signature and Response to Everolimus and Letrozole in Estrogen Receptor Positive Breast Cancer (2013) (82)
- Phase I Study of the Selective Aurora A Kinase Inhibitor MLN8054 in Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, and Pharmacodynamics (2010) (81)
- MONARCH1: Results from a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as monotherapy, in patients with HR+/HER2- breast cancer, after chemotherapy for advanced disease. (2016) (80)
- Systemic therapy emergencies. (2000) (80)
- European Cooperative Trial in Operable Breast Cancer (ECTO): Improved freedom from progression (FFP) from adding paclitaxel (T) to doxorubicin (A) followed by cyclophosphamide methotrexate and fluorouracil (CMF) (2005) (80)
- The AURORA initiative for metastatic breast cancer (2014) (79)
- Neoadjuvant Therapy as a Platform for Drug Development and Approval in Breast Cancer (2013) (79)
- Targeting the epidermal growth factor receptor with tyrosine kinase inhibitors: small molecules, big hopes. (2002) (79)
- A phase I dose-escalation study of XL147 (SAR245408), a PI3K inhibitor administered orally to patients (pts) with advanced malignancies. (2010) (78)
- New therapeutic agents targeting the epidermal growth factor receptor. (2000) (78)
- Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE). (2017) (78)
- Molecular approach to breast cancer treatment. (2004) (77)
- Molecular Pathways: AXL, a Membrane Receptor Mediator of Resistance to Therapy (2016) (77)
- CDK 8 is a colorectal cancer oncogene that regulates b-catenin activity (2008) (77)
- Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab. (2012) (76)
- Phase II study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. (2015) (75)
- Cardiac Safety of TGF-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Cancer Patients in a First-in-Human Dose Study (2014) (74)
- A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations (2019) (74)
- ZD1839 (‘Iressa’)1,2 as an Anticancer Agent (2012) (73)
- Objective response rate in a phase II multicenter trial of pertuzumab (P), a HER2 dimerization inhibiting monoclonal antibody, in combination with trastuzumab (T) in patients (pts) with HER2-positive metastatic breast cancer (MBC) which has progressed during treatment with T (2007) (73)
- Evaluation and Clinical Analyses of Downstream Targets of the Akt Inhibitor GDC-0068 (2013) (72)
- Randomized 3-arm, phase 2 study of temsirolimus (CCI-779) in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer (2005) (71)
- A phase I study of the oral mTOR inhibitor ridaforolimus (RIDA) in combination with the IGF-1R antibody dalotozumab (DALO) in patients (pts) with advanced solid tumors. (2010) (71)
- Metalloprotease-dependent protransforming growth factor-alpha ectodomain shedding in the absence of tumor necrosis factor-alpha-converting enzyme. (2001) (70)
- Combining the anti-EGFR agent gefitinib with chemotherapy in non-small-cell lung cancer: how do we go from INTACT to impact? (2004) (70)
- The cytoplasmic carboxy-terminal amino acid determines the subcellular localization of proTGF-(alpha) and membrane type matrix metalloprotease (MT1-MMP). (1999) (69)
- A phase I study with tumor molecular pharmacodynamic (MPD) evaluation of dose and schedule of the oral mTOR-inhibitor Everolimus (RAD001) in patients (pts) with advanced solid tumors (2005) (69)
- Unconventional Secretion is a Major Contributor of Cancer Cell Line Secretomes* (2012) (69)
- Objective regressions in non-small cell lung cancer patients treated in Phase I trials of oral ZD1839 (IressaTM), a selective tyrosine kinase inhibitor that blocks the epidermal growth factor receptor (EGFR) (2000) (68)
- High HER2 Expression Correlates with Response to the Combination of Lapatinib and Trastuzumab (2014) (67)
- A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer (2013) (67)
- Abstract CT-01: BYL719, a next generation PI3K alpha specific inhibitor: Preliminary safety, PK, and efficacy results from the first-in-human study (2012) (67)
- HER-Targeted Tyrosine-Kinase Inhibitors (2002) (67)
- years versus 1 year of adjuvant trastuzumab for HER 2-positive breast cancer ( HERA ) : an open-label , randomised controlled trial (2013) (66)
- Abstract S5-1: Biomarker analyses in CLEOPATRA: A phase III, placebo-controlled study of pertuzumab in HER2-positive, first-line metastatic breast cancer (MBC) (2012) (66)
- Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 (Her2) from colocalization: an in silico based mechanism (2011) (66)
- Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer. (2013) (66)
- Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA) (2013) (65)
- Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. (2019) (65)
- Treating cancer's kinase 'addiction' (2004) (64)
- Everolimus for postmenopausal women with advanced breast cancer: Updated results of the BOLERO-2 phase III trial. (2012) (64)
- Molecular prescreening to select patient population in early clinical trials (2012) (63)
- Targeted therapies in breast cancer: where are we now? (2008) (63)
- Nonpegylated Liposomal Doxorubicin (TLC-D99), Paclitaxel, and Trastuzumab in HER-2-Overexpressing Breast Cancer: A Multicenter Phase I/II Study (2009) (62)
- Taselisib (GDC-0032), a Potent β-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations (2015) (62)
- Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer. (2019) (62)
- Pan-Cancer Efficacy of Vemurafenib in BRAFV600-Mutant Non-Melanoma Cancers. (2020) (60)
- Pattern of rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: analysis from the NeoALTTO trial. (2013) (59)
- Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis. (2012) (59)
- Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients (2018) (59)
- Safety profile of Pertuzumab with Trastuzumab and Docetaxel in patients from Asia with human epidermal growth factor receptor 2-positive metastatic breast cancer: results from the phase III trial CLEOPATRA. (2014) (58)
- Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer (2008) (58)
- AACR Cancer Progress Report 2013 (2013) (58)
- A phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly (qW) MK-0646, an insulin-like growth factor-1 receptor (IGF1R) monoclonal antibody (MAb) in patients (pts) with advanced solid tumors (2008) (57)
- TGF-β signalling-related markers in cancer patients with bone metastasis (2008) (57)
- Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study. (2011) (57)
- Safety, pharmacokinetics, and preliminary activity of the alpha-specific PI3K inhibitor BYL719: Results from the first-in-human study. (2013) (57)
- Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors. (2003) (56)
- Pten loss promotes MAPK pathway dependency in HER2/neu breast carcinomas (2016) (55)
- Pilot trial of trastuzumab starting with or after the doxorubicin component of a doxorubicin plus paclitaxel regimen for women with HER2-positive advanced breast cancer. (2003) (55)
- Trastuzumab-DM1: building a chemotherapy-free road in the treatment of human epidermal growth factor receptor 2-positive breast cancer. (2011) (55)
- A first-in-human phase I study of BKM120, an oral pan-class I PI3K inhibitor, in patients (pts) with advanced solid tumors. (2010) (55)
- Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer. (2014) (55)
- A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics of XL765 (SAR245409), a PI3K/TORC1/TORC2 inhibitor administered orally to patients (pts) with advanced malignancies. (2010) (54)
- Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial (2016) (54)
- Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 study. (2013) (54)
- Impact of Genomics on Personalized Cancer Medicine (2012) (54)
- Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition. (2017) (53)
- Nadir CA-125 concentration in the normal range as an independent prognostic factor for optimally treated advanced epithelial ovarian cancer. (2008) (53)
- Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2) (2018) (53)
- Abstract PD01-01: Cetuximab + Cisplatin in Estrogen Receptor-Negative, Progesterone Receptor-Negative, HER2-Negative (Triple-Negative) Metastatic Breast Cancer: Results of the Randomized Phase II BALI-1 Trial (2010) (53)
- A new anti-ErbB2 strategy in the treatment of cancer: prevention of ligand-dependent ErbB2 receptor heterodimerization. (2002) (53)
- Phase I study of AZD0530, an oral potent inhibitor of Src kinase: First demonstration of inhibition of Src activity in human cancers (2007) (52)
- Receptor blockade with monoclonal antibodies as anti-cancer therapy. (1994) (52)
- Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2–positive early breast cancer: Analysis from the NeoALTTO (BIG 1‐06) and ALTTO (BIG 2‐06) trials (2018) (51)
- 18F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials (2016) (51)
- SOLTI-0701: A Multinational Double-Blind, Randomized Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo When Administered in Combination with Capecitabine in Patients with Locally Advanced or Metastatic Breast Cancer (BC). (2009) (51)
- Current and planned clinical trials with trastuzumab (Herceptin). (2000) (49)
- Clinical response to a lapatinib-based therapy for a Li-Fraumeni syndrome patient with a novel HER2V659E mutation. (2013) (49)
- Correlation of molecular alterations with efficacy of everolimus in hormone receptor–positive, HER2-negative advanced breast cancer: Results from BOLERO-2. (2013) (49)
- Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2. (2018) (49)
- HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2 (2017) (49)
- Phase I dose-escalation study of XL147, a PI3K inhibitor administered orally to patients with solid tumors. (2009) (49)
- Antitumor Activity of the Hsp90 Inhibitor IPI-504 in HER2-Positive Trastuzumab-Resistant Breast Cancer (2011) (49)
- Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors. (2012) (48)
- Targeting epidermal growth factor receptor in lung cancer (2002) (48)
- Impaired Trafficking and Activation of Tumor Necrosis Factor-α-converting Enzyme in Cell Mutants Defective in Protein Ectodomain Shedding* (2003) (48)
- p95HER2–T cell bispecific antibody for breast cancer treatment (2018) (48)
- Future options with trastuzumab for primary systemic and adjuvant therapy. (2004) (48)
- Evaluation of lapatinib (Lap) plus capecitabine (Cap) in patients with brain metastases (BM) from HER2+ breast cancer (BC) enrolled in the Lapatinib Expanded Access Program (LEAP) and French Authorisation Temporaire d'Utilisation (ATU) (2008) (47)
- Updated Survival Analysis of a Randomized Study of Lapatinib Alone or in Combination with Trastuzumab in Women with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab Therapy. (2009) (47)
- Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial (2019) (47)
- Epithelial growth factor receptor interacting agents. (2002) (47)
- A dose-escalation study with the novel formulation of the oral pan-class I PI3K inhibitor BEZ235, solid dispersion system (SDS) sachet, in patients with advanced solid tumors. (2011) (46)
- Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1E17K-Mutant, ER-Positive Metastatic Breast Cancer (2020) (46)
- Erlotinib in combination with capecitabine and docetaxel in patients with metastatic breast cancer: a dose-escalation study. (2008) (46)
- Is circulating HER-2 more than just a tumor marker? (2001) (46)
- Treatment of cancer with oral drugs: a position statement by the Spanish Society of Medical Oncology (SEOM) (2010) (46)
- Erratum to: Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis (2014) (46)
- Abstract S5-2: HERA TRIAL: 2 years versus 1 year of trastuzumab after adjuvant chemotherapy in women with HER2-positive early breast cancer at 8 years of median follow up (2012) (46)
- Neoadjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer: primary efficacy analysis of the NOAH trial. (2009) (45)
- AKT signaling in ERBB2-amplified breast cancer. (2016) (45)
- Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer. (2019) (45)
- Clinical trials of single-agent trastuzumab (Herceptin). (2000) (45)
- Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation study (2008) (45)
- 687 Beta-catenin Confers Resistance to PI3K and AKT Inhibitors and Subverts FOXO3a to Promote Metastasis in Colon Cancer (2012) (44)
- Paclitaxel With Inhibitor of Apoptosis Antagonist, LCL161, for Localized Triple-Negative Breast Cancer, Prospectively Stratified by Gene Signature in a Biomarker-Driven Neoadjuvant Trial. (2018) (44)
- The hVps34‐SGK3 pathway alleviates sustained PI3K/Akt inhibition by stimulating mTORC1 and tumour growth (2016) (44)
- PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab. (2018) (44)
- A multi-histology basket trial of ado-trastuzumab emtansine in patients with HER2 amplified cancers. (2018) (44)
- Neoadjuvant trastuzumab in locally advanced breast cancer (NOAH): Antitumour and safety analysis (2007) (43)
- Combination of the mTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical Trial (2014) (43)
- Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors (2015) (43)
- Abstract S1-11: Meta-analysis Results from the Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC) (2012) (42)
- Abstract LB-64: GDC-0032, a beta isoform-sparing PI3K inhibitor: Results of a first-in-human phase Ia dose escalation study. (2013) (42)
- PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab. (2019) (42)
- Stratification and therapeutic potential of PML in metastatic breast cancer (2016) (42)
- S3-7: Everolimus for Postmenopausal Women with Advanced Breast Cancer: Updated Results of the BOLERO-2 Phase III Trial. (2011) (42)
- Potential biomarkers of long‐term benefit from single‐agent trastuzumab or lapatinib in HER2‐positive metastatic breast cancer (2014) (42)
- Effect of p95HER2/611CTF on the response to trastuzumab and chemotherapy. (2014) (42)
- Abstract LB-63: Relationship between tumor biomarkers (BM) and efficacy in EMILIA, a phase III study of trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC). (2013) (42)
- Advances in the management of HER2-positive early breast cancer. (2017) (41)
- A multicentre phase II gene expression profiling study of putative relationships between tumour biomarkers and clinical response with erlotinib in non-small-cell lung cancer (2010) (41)
- Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor–Positive Advanced Breast Cancer (2018) (41)
- Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06) (2017) (40)
- First human dose (FHD) study of the oral transforming growth factor-beta receptor I kinase inhibitor LY2157299 in patients with treatment-refractory malignant glioma. (2011) (40)
- Factors associated with surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the NeoALTTO phase III trial. (2013) (40)
- Pertuzumab monotherapy following trastuzumab-based treatment: Activity and tolerability in patients with advanced HER2- positive breast cancer. (2016) (40)
- Tumor genetic testing for patient selection in phase I clinical trials: the case of PI3K inhibitors. (2012) (40)
- First human dose escalation study in patients with metastatic malignancies to determine safety and pharmacokinetics of LY2157299, a small molecule inhibitor of the transforming growth factor-beta receptor I kinase (2008) (40)
- Cetuximab and Radiotherapy in Laryngeal Preservation for Cancers of the Larynx and Hypopharynx: A Secondary Analysis of a Randomized Clinical Trial. (2016) (39)
- A phase I dose-escalation study of LDE225, a smoothened (Smo) antagonist, in patients with advanced solid tumors. (2010) (39)
- [Breast cancer in the early stage]. (2012) (39)
- Dose-dependent inhibition of the EGFR and signalling pathways with the anti-EGFR monoclonal antibody (MAb) EMD 72000 administered every three weeks (q3w). A phase I pharmacokinetic/pharmacodynamic (PK/PD) study to define the optimal biological dose (OBD). (2004) (38)
- Correlation of molecular alterations with efficacy of everolimus in hormone receptor-positive, HER2-negative advanced breast cancer: Results from BOLERO-2. (2013) (38)
- Randomized, double-blind, multicenter trial comparing two doses of arzoxifene (LY353381) in hormone-sensitive advanced or metastatic breast cancer patients. (2003) (38)
- Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy (2018) (38)
- Combined anti-EGF receptor and anti-HER2 receptor therapy in breast cancer: a promising strategy ready for clinical testing. (2002) (38)
- A phase 3 tRial comparing capecitabinE in combination with SorafenIb or pLacebo for treatment of locally advanced or metastatIc HER2-Negative breast CancEr (the RESILIENCE study): study protocol for a randomized controlled trial (2013) (38)
- Phase II, 3-arm study of CCI-779 in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer: preliminary results. (2004) (38)
- Tissue sampling in lung cancer: a review in light of the MERIT experience. (2011) (38)
- Successful Targeted Therapy of Refractory Pediatric ETV6-NTRK3 Fusion-Positive Secretory Breast Carcinoma. (2017) (38)
- Abstract P6-10-07: Phase I study of BYL719, an alpha-specific PI3K inhibitor, in patients withPIK3CAmutant advanced solid tumors: preliminary efficacy and safety in patients withPIK3CAmutant ER-positive (ER+) metastatic breast cancer (MBC) (2012) (37)
- Combination of a MEK inhibitor, pimasertib (MSC1936369B), and a PI3K/mTOR inhibitor, SAR245409, in patients with advanced solid tumors: Results of a phase Ib dose-escalation trial. (2013) (37)
- Open label, randomized, phase II study of pertuzumab (P) in patients (pts) with metastatic breast cancer (MBC) with low expression of HER2 (2005) (37)
- A phase I/IB dose-escalation study of BEZ235 in combination with trastuzumab in patients with PI3-kinase or PTEN altered HER2+ metastatic breast cancer. (2012) (37)
- Optimal dose of cetuximab (C) given every 2 weeks (q2w): A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly (q1w) and q2w schedules in patients (pts) with metastatic colorectal cancer (mCRC). (2006) (37)
- Targeted therapy in advanced colon cancer: the role of new therapies. (2004) (36)
- Prevalence of clonal hematopoiesis of indeterminate potential (CHIP) measured by an ultra-sensitive sequencing assay: Exploratory analysis of the Circulating Cancer Genome Atlas (CCGA) study. (2018) (36)
- Benefit to neoadjuvant anti-human epidermal growth factor receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) status. (2015) (36)
- Batch effects correction improves the sensitivity of significance tests in spectral counting-based comparative discovery proteomics. (2012) (36)
- Efficacy of Vemurafenib in Patients With Non–Small-Cell Lung Cancer With BRAF V600 Mutation: An Open-Label, Single-Arm Cohort of the Histology-Independent VE-BASKET Study (2019) (36)
- PI3K Inhibition Activates SGK1 via a Feedback Loop to Promote Chromatin-Based Regulation of ER-Dependent Gene Expression. (2019) (36)
- Improved preservation of larynx with the addition of cetuximab to radiation for cancers of the larynx and hypopharynx (2005) (36)
- Pegylated liposomal doxorubicin plus cyclophosphamide followed by paclitaxel as primary chemotherapy in elderly or cardiotoxicity-prone patients with high-risk breast cancer: results of the phase II CAPRICE study (2015) (35)
- Therapeutic Benefit of Selective Inhibition of p110α PI3-Kinase in Pancreatic Neuroendocrine Tumors (2016) (35)
- 350O_PRFINAL OVERALL SURVIVAL (OS) ANALYSIS FROM THE CLEOPATRA STUDY OF FIRST-LINE (1L) PERTUZUMAB (PTZ), TRASTUZUMAB (T), AND DOCETAXEL (D) IN PATIENTS (PTS) WITH HER2-POSITIVE METASTATIC BREAST CANCER (MBC) (2014) (35)
- Feasibility Trial of Methotrexate–Paclitaxel as a Second Line Therapy in Advanced Urothelial Cancer (2002) (35)
- Pancancer modelling predicts the context-specific impact of somatic mutations on transcriptional programs (2017) (34)
- Risk of recurrence during follow-up for optimally treated advanced epithelial ovarian cancer (EOC) with a low-level increase of serum CA-125 levels. (2009) (34)
- Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: results from the HERA trial. (2013) (34)
- Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer (2018) (34)
- Therapeutic monoclonal antibodies in oncology: an update: Monoclonal antibodies directed at growth factor receptors (2000) (34)
- Circulating tumor cells and response to neoadjuvant paclitaxel and HER2-targeted therapy: a sub-study from the NeoALTTO phase III trial. (2013) (34)
- Cetuximab in recurrent/metastatic (R&M) squamous cell carcinoma of the head and neck (SCCHN) refractory to first-line platinum-based therapies (2005) (34)
- The carboxy-terminal cysteine of the tetraspanin L6 antigen is required for its interaction with SITAC, a novel PDZ protein. (2000) (34)
- VE-BASKET, a Simon 2-stage adaptive design, phase II, histology-independent study in nonmelanoma solid tumors harboring BRAF V600 mutations (V600m): Activity of vemurafenib (VEM) with or without cetuximab (CTX) in colorectal cancer (CRC). (2014) (34)
- TGF-beta signalling-related markers in cancer patients with bone metastasis. (2008) (34)
- HER2 Carboxyl-terminal Fragments Regulate Cell Migration and Cortactin Phosphorylation* (2009) (34)
- New drugs and new approaches in metastatic bladder cancer. (2003) (34)
- Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265P mutations. (2017) (33)
- Skin as a surrogate tissue for pharmacodynamic end points: is it deep enough? (2003) (33)
- The hVps34‐SGK3 pathway alleviates sustained PI3K/Akt inhibition by stimulating mTORC1 and tumour growth (2016) (33)
- Plasma miRNA Levels for Predicting Therapeutic Response to Neoadjuvant Treatment in HER2-positive Breast Cancer: Results from the NeoALTTO Trial (2019) (33)
- Breast cancer cell-free DNA (cfDNA) profiles reflect underlying tumor biology: The Circulating Cell-Free Genome Atlas (CCGA) study. (2018) (33)
- Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer. (2011) (32)
- A multicenter, open-label phase II trial of dovitinib, an FGFR1 inhibitor, in FGFR1 amplified and non-amplified metastatic breast cancer. (2011) (32)
- A Pharmacodynamic/Pharmacokinetic Study of Ficlatuzumab in Patients with Advanced Solid Tumors and Liver Metastases (2014) (32)
- Pharmacodynamic studies of tumor biopsy specimens from patients with advanced gastric carcinoma undergoing treatment with genfinitib (ZD1839) (2003) (31)
- Phase I pharmacokinetic and pharmacodynamic study of weekly 1-hour and 24-hour infusion BMS-214662, a farnesyltransferase inhibitor, in patients with advanced solid tumors. (2005) (31)
- Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer: overall survival and updated progression-free survival results from a phase II study (2016) (31)
- Oncologist use and perception of large panel next-generation tumor sequencing (2017) (31)
- Correlation of molecular alterations with efficacy of everolimus in hormone-receptor-positive, HER2-negative advanced breast cancer: Results from BOLERO-2. (2013) (31)
- Differential Receptor Tyrosine Kinase PET Imaging for Therapeutic Guidance (2016) (31)
- Erratum: Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients (2017) (30)
- SOLTI NeoPARP: a phase II randomized study of two schedules of iniparib plus paclitaxel versus paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer (2015) (30)
- The PI3-K/AKT/mTOR pathway as a target for breast cancer therapy (2007) (30)
- SANDPIPER: Phase III study of the PI3-kinase (PI3K) inhibitor taselisib (GDC-0032) plus fulvestrant in patients (pts) with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer (BC) enriched for pts with PIK3CA-mutant tumors. (2016) (30)
- FOXA1 Mutations Reveal Distinct Chromatin Profiles and Influence Therapeutic Response in Breast Cancer. (2020) (30)
- Correction to: De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 (Annals of Oncology (2017) 28(8) (1700–1712), (S0923753419321817), (10.1093/annonc/mdx308)) (2017) (29)
- Abstract S1-01: The association between event-free survival and pathological complete response to neoadjuvant lapatinib, trastuzumab or their combination in HER2-positive breast cancer. Survival follow-up analysis of the NeoALTTO study (BIG 1-06) (2013) (29)
- Effects of Src kinase inhibition by saracatinib (AZD0530) on bone turnover in advanced malignancy in a Phase I study. (2012) (29)
- PIK3CA Status in Circulating Tumor DNA Predicts Efficacy of Buparlisib Plus Fulvestrant in Postmenopausal Women With Endocrine-resistant HR+/HER2- Advanced Breast Cancer: First Results From the Randomized, Phase III BELLE-2 Trial (2015) (29)
- Association of human papillomavirus and p16 status with mucositis and dysphagia for head and neck cancer patients treated with radiotherapy with or without cetuximab: Assessment from a phase 3 registration trial (2016) (29)
- Five-day course of granulocyte colony-stimulating factor in patients with prolonged neutropenia after adjuvant chemotherapy for breast cancer is a safe and cost-effective schedule to maintain dose-intensity. (1996) (29)
- Sequential adjuvant therapy: the Memorial Sloan-Kettering Cancer Center experience. (1996) (29)
- FGF4 dissociates anti-tumorigenic from differentiation signals of retinoic acid in human embryonal carcinomas (1998) (29)
- Clinical trials of Herceptin(R) (trastuzumab). (2001) (29)
- Colon cancer-derived oncogenic EGFR G724S mutant identified by whole genome sequence analysis is dependent on asymmetric dimerization and sensitive to cetuximab (2014) (28)
- Concerted escalation of dose and dosing duration in a phase I study of the oral camptothecin gimatecan (ST1481) in patients with advanced solid tumors. (2007) (28)
- 2030 ORAL Efficacy of neoadjuvant trastuzumab in patients with inflammatory breast cancer: data from the NOAH (NeOAdjuvant Herceptin) Phase III trial (2007) (28)
- AACR Cancer Progress Report 2015 (2015) (28)
- RESILIENCE: Phase III Randomized, Double‐Blind Trial Comparing Sorafenib With Capecitabine Versus Placebo With Capecitabine in Locally Advanced or Metastatic HER2‐Negative Breast Cancer (2017) (28)
- Dual human epidermal growth factor receptor 2 (HER2) blockade and hormonal therapy for the treatment of primary HER2-positive breast cancer: one more step toward chemotherapy-free therapy. (2013) (28)
- Anti-HER 2 Immunoliposomes : Enhanced Efficacy Attributable to Targeted Delivery 1 (2002) (27)
- Phase II trial of the novel taxane BMS-184476 as second-line in non-small-cell lung cancer. (2005) (27)
- Prospective Blinded Study of BRAFV600E Mutation Detection in Cell-Free DNA of Patients with Systemic Histiocytic Disorders (2014) (27)
- Phase I Pharmacokinetic/Pharmacodynamic Study of EKB-569, an Irreversible Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Combination with Irinotecan, 5-Fluorouracil, and Leucovorin (FOLFIRI) in First-Line Treatment of Patients with Metastatic Colorectal Cancer (2008) (27)
- Anticancer activity of the type I insulin-like growth factor receptor antagonist, ganitumab, in combination with the death receptor 5 agonist, conatumumab (2015) (26)
- A Naturally Occurring HER 2 Carboxy-Terminal Fragment Promotes Mammary Tumor Growth and Metastasis † (2009) (26)
- Overall survival (OS) update of the double-blind placebo (PBO)-controlled randomized phase 2 LOTUS trial of first-line ipatasertib (IPAT) + paclitaxel (PAC) for locally advanced/metastatic triple-negative breast cancer (mTNBC). (2018) (26)
- An effect size filter improves the reproducibility in spectral counting-based comparative proteomics. (2013) (26)
- Phase I study of AEE788, a novel multitargeted inhibitor of ErbB and VEGF receptor family tyrosine kinases: A pharmacokinetic (PK)-pharmacodynamic (PD) study to identify the optimal therapeutic dose regimen (2005) (26)
- Phosphoinositide 3-Kinase Mutations in Breast Cancer: A “Good” Activating Mutation? (2009) (26)
- Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2. (2014) (25)
- Weekly docetaxel in breast cancer: applying clinical data to patient therapy. (2001) (25)
- 3LBA SOLTI-0701: A double-blind, randomized phase 2b study evaluating the efficacy and safety of sorafenib (SOR) compared to placebo (PL) when administered in combination with capecitabine (CAP) in patients (pts) with locally advanced (adv) or metastatic (met) breast cancer (BC) (2009) (25)
- Inactivating mutations block the tumor necrosis factor-alpha-converting enzyme in the early secretory pathway. (2004) (25)
- P176 Cardiac safety guidelines for the adjuvant use of trastuzumab (Herceptin®) in HER2-positive early breast cancer (2007) (25)
- Oral PI3 kinase inhibitor BKM120 monotherapy in patients (pts) with advanced solid tumors: An update on safety and efficacy. (2011) (24)
- Improved clinical and cell cycle response with an mTOR inhibitor, daily oral RAD001 (everolimus) plus letrozole versus placebo plus letrozole in a randomized phase II neoadjuvant trial in ER+ breast cancer (2008) (24)
- Results of a phase II study of liposomal doxorubicin (Myocet®) in combination with weekly paclitaxel and trastuzumab (Herceptin®) In patients with HER2-positive locally advanced or metastatic breast cancer (LA/MBC) (2004) (24)
- Vemurafenib in Patients With Relapsed Refractory Multiple Myeloma Harboring BRAF V600 Mutations: A Cohort of the Histology-Independent VE-BASKET Study. (2018) (24)
- A phase II study of the PI3K inhibitor taselisib (GDC-0032) combined with fulvestrant (F) in patients (pts) with HER2-negative (HER2-), hormone receptor-positive (HR+) advanced breast cancer (BC). (2016) (24)
- Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab (2017) (23)
- Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes. (1995) (23)
- Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab. (2012) (23)
- Abstract PD5-2: Ph1b study of the PI3K inhibitor taselisib (GDC-0032) in combination with letrozole in patients with hormone receptor-positive advanced breast cancer (2015) (23)
- Breast cancer in 2010: Novel targets and therapies for a personalized approach (2011) (23)
- The ErbB Receptors as Targets for Breast Cancer Therapy (1999) (23)
- P118 ALTTO (adjuvant lapatinib and/or trastuzumab treatment optimisation) study [BIG 2-06/N063D/EGF106708]: a phase III study for HER2-overexpressing early breast cancer (BC) (2007) (23)
- Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of HDM-2 antagonist JNJ-26854165 in patients with advanced refractory solid tumors. (2009) (23)
- Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2-Positive Early Stage Breast Cancer: A Single Center Experience. (2017) (23)
- Keeping faith with trial volunteers (2007) (23)
- Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy (2020) (23)
- Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors. (2012) (22)
- Cell-free DNA (cfDNA) mutations from clonal hematopoiesis: Implications for interpretation of liquid biopsy tests. (2017) (22)
- Targeting a cell state common to triple-negative breast cancers (2015) (22)
- Need for global action for cancer control. (2008) (22)
- Gemcitabine/paclitaxel-based three-drug regimens in advanced urothelial cancer. (2000) (22)
- Oncologic therapy shapes the fitness landscape of clonal hematopoiesis (2019) (22)
- Bringing precision medicine to the clinic: from genomic profiling to the power of clinical observation. (2013) (22)
- Combined antiangiogenesis and antiepidermal growth factor receptor targeting in the treatment of cancer: hold back, we are not there yet. (2007) (22)
- Analysis of regional timelines to set up a global phase III clinical trial in breast cancer: the adjuvant lapatinib and/or trastuzumab treatment optimization experience. (2013) (22)
- Cooperative antiproliferative effects of 8-chloro-cyclic AMP and 528 anti-epidermal growth factor receptor monoclonal antibody on human cancer cells. (1995) (22)
- Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2. (2019) (21)
- A phase I study of MEHD7945A (MEHD), a first-in-class HER3/EGFR dual-action antibody, in patients (pts) with refractory/recurrent epithelial tumors: Expansion cohorts. (2012) (21)
- LBA10_PRPrimary results of LORELEI: A phase II randomized, double-blind study of neoadjuvant letrozole (LET) plus taselisib versus LET plus placebo (PLA) in postmenopausal patients (pts) with ER+/HER2-negative early breast cancer (EBC) (2017) (21)
- S25 Update of the HERA trial and the role of 1 year Trastuzumab as adjuvant therapy for breast cancer (2009) (21)
- Epidermal growth factor receptor pathway inhibitors. (2006) (21)
- All-trans-retinoic acid and hexamethylene bisacetamide (HMBA) regulate TGF-alpha and Hst-1/kFGF expression in differentiation sensitive but not in resistant human teratocarcinomas. (1994) (21)
- Abstract P5-18-26: Confirmatory overall survival (OS) analysis of CLEOPATRA: a randomized, double-blind, placebo-controlled Phase III study with pertuzumab (P), trastuzumab (T), and docetaxel (D) in patients (pts) with HER2-positive first-line (1L) metastatic breast cancer (MBC) (2012) (21)
- Absence of pharmacokinetic drug–drug interaction of pertuzumab with trastuzumab and docetaxel (2013) (21)
- Abstract P6-04-02: Final progression-free survival analysis of BOLERO-2: a phase III trial of everolimus for postmenopausal women with advanced breast cancer (2012) (21)
- First-in-human phase I study evaluating the safety, pharmacokinetics (PK), and intratumor pharmacodynamics (PD) of the novel, oral, ATP-competitive Akt inhibitor GDC-0068. (2011) (21)
- Combination of the mammalian target of rapamycin (mTOR) inhibitor everolimus (E) with the insulin like growth factor-1-receptor (IGF-1-R) inhibitor NVP-AEW-541: A mechanistic based anti-tumor strategy (2005) (20)
- Response to neoadjuvant trastuzumab and chemotherapy in ER+ and ER- HER2-positive breast cancers: Gene expression analysis. (2011) (20)
- Follow-up results of NOAH, a randomized phase III trial evaluating neoadjuvant chemotherapy with trastuzumab (CT+H) followed by adjuvant H versus CT alone, in patients with HER2-positive locally advanced breast cancer. (2013) (20)
- Pertuzumab and Trastuzumab: Re-Responses to 2 Biological Agents in Patients with HER2-Positive Breast Cancer Which Had Previously Progressed during Therapy with Each Agent Given Separately: A New Biological and Clinical Observation. (2009) (20)
- Correlation of KRAS status (wild type [wt] vs. mutant [mt]) with efficacy to first-line cetuximab in a study of cetuximab single agent followed by cetuximab + FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC) (2008) (20)
- 1LBA Everolimus plus exemestane for hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2–) advanced breast cancer (BC): overall survival results from BOLERO-2 (2014) (20)
- Health-related quality of life and disease symptoms in postmenopausal women with HR+, HER2− advanced breast cancer treated with everolimus plus exemestane versus exemestane monotherapy (2013) (20)
- MET activation confers resistance to cetuximab, and prevents HER2 and HER3 upregulation in head and neck cancer (2019) (19)
- Phase I study of LJM716, BYL719, and trastuzumab in patients (pts) with HER2-amplified (HER2+) metastatic breast cancer (MBC). (2015) (19)
- A phase I dose-escalating study of ES-285, a marine sphingolipid-derived compound, with repeat dose administration in patients with advanced solid tumors (2012) (19)
- Anti-HER2 Immunoliposomes (2002) (19)
- Biomarkers as potential predictors of pathologic complete response (pCR) in the NOAH trial of neoadjuvant trastuzumab in patients (pts) with HER2-positive locally advanced breast cancer (LABC) (2008) (19)
- Whole-genome sequencing and cancer therapy: is too much ever enough? (2012) (19)
- A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer (2017) (19)
- VE-BASKET, a first-in-kind, phase II, histology-independent "basket" study of vemurafenib (VEM) in nonmelanoma solid tumors harboring BRAF V600 mutations (V600m). (2014) (19)
- Pharmacology in the Era of Targeted Therapies: The Case of PI3K Inhibitors (2016) (19)
- Predictive biomarker discovery and validation for the targeted chemotherapeutic ixabepilone. (2006) (19)
- Abstract S2-07: cfDNA analysis from BOLERO-2 plasma samples identifies a high rate of ESR1 mutations: Exploratory analysis for prognostic and predictive correlation of mutations reveals different efficacy outcomes of endocrine therapy–based regimens (2016) (19)
- Next-Generation Sequencing-Based Assessment of JAK2, PD-L1, and PD-L2 Copy Number Alterations at 9p24.1 in Breast Cancer: Potential Implications for Clinical Management. (2019) (19)
- Quality of life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer. (2012) (19)
- Schedule-dependent effects of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib in combination with the mammalian target of rapamycin (mTOR) inhibitor everolimus (RAD001). (2004) (19)
- Monoclonal antibodies directed at growth factor receptors. (2000) (19)
- Abstract OT2-6-08: Phase II, randomized, parallel-cohort study of neoadjuvant buparlisib (BKM120) in combination with trastuzumab and paclitaxel in women with HER2-positive, PIK3CA mutant and PIK3CA wild-type primary breast cancer – NeoPHOEBE (2013) (18)
- Phase I-IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours. (2013) (18)
- Abstract PD5-5: Phase I study of the PI3Kα inhibitor BYL719 plus fulvestrant in patients withPIK3CA-altered and wild type ER+/HER2- locally advanced or metastatic breast cancer (2015) (18)
- Phase II genomics study in patients receiving ixabepilone as neoadjuvant treatment for breast cancer (BC): Preliminary efficacy and safety data (2005) (18)
- Methodological aspects of the molecular and histological study of prostate cancer: Focus on PTEN (2015) (18)
- Type I Receptor Tyrosine Kinases as Targets for Therapy in Breast Cancer (2004) (18)
- How to treat hormone receptor-positive, human epidermal growth factor receptor 2-amplified breast cancer. (2009) (18)
- Is there a role for the irreversible epidermal growth factor receptor inhibitor EKB-569 in the treatment of cancer? A mutation-driven question. (2006) (18)
- Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer. (2014) (18)
- Adverse events with pertuzumab and trastuzumab: Evolution during treatment with and without docetaxel in CLEOPATRA. (2012) (17)
- Abstract LB-147: Combination of the MEK inhibitor, pimasertib (MSC1936369B), and the PI3K/mTOR inhibitor, SAR245409, in patients with advanced solid tumors: Results of a phase Ib dose-escalation trial. (2013) (17)
- Phase I evaluation of the safety of conatumumab (AMG 655) in combination with AMG 479 in patients (pts) with advanced, refractory solid tumors. (2010) (17)
- A phase I trial of weekly combination KOS-862 (Epothilone D) and trastuzumab in HER-2 overexpressing malignancies. (2006) (17)
- APHINITY trial (BIG 4-11): A randomized comparison of chemotherapy (C) plus trastuzumab (T) plus placebo (Pla) versus chemotherapy plus trastuzumab (T) plus pertuzumab (P) as adjuvant therapy in patients (pts) with HER2-positive early breast cancer (EBC). (2017) (17)
- Antitumor activity of cediranib in patients with metastatic or recurrent head and neck cancer (HNC) or recurrent non-small cell lung cancer (NSCLC): An open-label exploratory study. (2016) (16)
- MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer (2015) (16)
- Abstract CT231: A first-in-human phase I study to evaluate the oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with estrogen receptor+ HER2-, advanced/metastatic breast cancer (2015) (16)
- The oral transforming growth factor-beta (TGF-ß) receptor I kinase inhibitor LY2157299 plus lomustine in patients with treatment-refractory malignant glioma: The first human dose study. (2012) (16)
- Abstract LB-65: Towards defining the genetic framework for clinical response to treatment with BYL719, a PI3Kalpha-specific inhibitor. (2013) (16)
- Clinical surrogate markers of survival in advanced non-small cell lung cancer (NSCLC) patients treated with second-third line erlotinib. (2009) (16)
- The tumor suppressor PTEN and the PDK1 kinase regulate formation of the columnar neural epithelium (2016) (16)
- Paclitaxel for breast cancer: the Memorial Sloan-Kettering Cancer Center experience. (1997) (15)
- A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer (2017) (15)
- Superiority of sequential versus concurrent administration of paclitaxel with etoposide in advanced non-small cell lung cancer: comparison of two Phase II trials. (1998) (15)
- Fat embolism syndrome following bone marrow harvesting. (1991) (15)
- The era of cancer discovery. (2011) (15)
- IPATunity130: A pivotal randomized phase III trial evaluating ipatasertib (IPAT) + paclitaxel (PAC) for PIK3CA/AKT1/PTEN-altered advanced triple-negative (TN) or hormone receptor-positive HER2-negative (HR+/HER2–) breast cancer (BC). (2018) (15)
- TARGETING THE MUC 1-C ONCOPROTEIN DOWNREGULATES HER 2 ACTIVATION AND ABROGATES TRASTUZUMAB RESISTANCE IN BREAST CANCER CELLS (2014) (15)
- Abstract PD5-05: Neratinib forERBB2mutant, HER2 non-amplified, metastatic breast cancer: Preliminary analysis from a multicenter, open-label, multi-histology phase II basket trial (2016) (15)
- High β-III tubulin expression in triple-negative (TN) breast cancer (BC) subtype and correlation to ixabepilone response: A retrospective analysis. (2016) (15)
- Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in the CLEOPATRA study. (2012) (15)
- Abstract CT001: Neratinib inHER2orHER3mutant solid tumors: SUMMIT, a global, multi-histology, open-label, phase 2 "basket" study (2017) (15)
- Abstract PD3-06: Updated results from DESTINY-breast01, a phase 2 trial of trastuzumab deruxtecan (T-DXd ) in HER2 positive metastatic breast cancer (2021) (15)
- Abstract PD2-08: Neratinib + fulvestrant inERBB2-mutant, HER2–non-amplified, estrogen receptor (ER)-positive, metastatic breast cancer (MBC): Preliminary analysis from the phase II SUMMIT trial (2017) (14)
- Abstract PD1-3: Ph1b study of the PI3K inhibitor GDC-0032 in combination with fulvestrant in patients with hormone receptor-positive advanced breast cancer (2013) (14)
- Abstract B109: AZD5363, a catalytic pan-Akt inhibitor, inAkt1E17K mutation positive advanced solid tumors (2015) (14)
- Using Pharmacokinetic and Pharmacodynamic Data in Early Decision Making Regarding Drug Development: A Phase I Clinical Trial Evaluating Tyrosine Kinase Inhibitor, AEE788 (2012) (14)
- Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab. (2016) (14)
- Treatment of HER2-positive metastatic breast cancer. (2015) (14)
- Analysis and variability of TGFβ measurements in cancer patients with skeletal metastases (2008) (14)
- A multicenter, open-label phase II trial of dovitinib, a fibroblast growth factor receptor 1 (FGFR1) inhibitor, in FGFR1-amplified and nonamplified metastatic breast cancer (BC). (2011) (14)
- LBA8A PHASE III RANDOMIZED, DOUBLE-BLIND, TRIAL COMPARING SORAFENIB PLUS CAPECITABINE VERSUS PLACEBO PLUS CAPECITABINE IN THE TREATMENT OF LOCALLY ADVANCED OR METASTATIC HER2-NEGATIVE BREAST CANCER (RESILIENCE) (2014) (14)
- Efficacy and safety of retaspimycin hydrochloride (IPI-504) in combination with trastuzumab in patients (pts) with pretreated, locally advanced or metastatic HER2-positive breast cancer. (2011) (14)
- S5-5: A Phase III, Randomized, Double-Blind, Placebo-Controlled Registration Trial To Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Patients with Previously Untreated HER2−Positive Metastatic Breast Cancer (CLEOPATRA). (2011) (14)
- Integrated data review of the first-in-human dose (FHD) study evaluating safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the oral transforming growth factor-beta (TGF-ß) receptor I kinase inhibitor, LY2157299 monohydrate (LY). (2013) (13)
- A dominant-negative N-terminal fragment of HER2 frequently expressed in breast cancers (2013) (13)
- Debio 1347, an oral FGFR inhibitor: Results from a first-in-human, phase I dose-escalation study in patients with FGFR genomically activated advanced solid tumors. (2017) (13)
- Summary of results in patients with metastatic renal cell cancer (RCC) from phase I studies of RAD001 (everolimus). (2006) (13)
- New horizons: gene therapy for cancer. (1999) (13)
- OT1-02-04: Adjuvant Pertuzumab and Herceptin IN IniTial TherapY of Breast Cancer: APHINITY (BIG 4–11/BO25126/TOC4939g). (2011) (13)
- Safety profile of Herceptin (R) as a single agent and in combination with chemotherapy (1999) (13)
- Over-expression of transforming growth factor alpha antagonizes the anti-tumorigenic but not the differentiation actions of retinoic acid in a human teratocarcinoma cell. (1993) (13)
- A phase 1 dose-escalation study of anti-HER3 monoclonal antibody LJM716 in combination with trastuzumab in patients with HER2-overexpressing metastatic breast or gastric cancer. (2014) (13)
- ASSOCIATION BETWEEN TUMOR EGFR AND KRAS MUTATION STATUS AND CLINICAL OUTCOMES IN NSCLC PATIENTS RANDOMIZED TO SORAFENIB PLUS BEST SUPPORTIVE CARE ( BSC ) OR BSC ALONE : SUBANALYSIS OF THE PHASE III MISSION TRIAL (2012) (13)
- The use of breast imaging for predicting response to neoadjuvant lapatinib, trastuzumab and their combination in HER2-positive breast cancer: Results from Neo-ALTTO. (2018) (13)
- A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer (2017) (13)
- Phase I study of humanized IgG1 anti-epidermal growth factor receptor (EGFR) monoclonal antibody EMD 72000 plus gemcitabine (Gem) in advanced pancreatic cancer. (2004) (13)
- Sequential dose-dense paclitaxel followed by topotecan in untreated extensive-stage small-cell lung cancer: a Spanish Lung Cancer Group phase II study. (2003) (13)
- Who will benefit from treatment against EGFR? (2005) (13)
- Cancer Therapy : Preclinical Dual mTORC 1 / 2 and HER 2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-HER 2 Therapy (2012) (12)
- Ph III randomized studies of the oral pan-PI3K inhibitor buparlisib (BKM120) with fulvestrant in postmenopausal women with HR+/HER2– locally advanced or metastatic breast cancer (BC) after aromatase inhibitor (AI; BELLE-2) or AI and mTOR inhibitor (BELLE-3) treatment. (2013) (12)
- The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoALTTO study. (2018) (12)
- Hera Trial: 2 Years Versus 1 Year of Trastuzumab After Adjuvant Chemotherapy in Women with Her2-Positive Early Breast Cancer at 8 Years of Median Follow up (2012) (12)
- Vemurafenib (VEM) in Relapsed Refractory Multiple Myeloma Harboring BRAF V600 Mutations (V600m): A Cohort of the Histology-Independent VE-Basket Study (2015) (12)
- HER2 signatures in breast cancer: ready to go to print? (2010) (12)
- Phase I study of escalating doses of edatrexate in combination with paclitaxel in patients with metastatic breast cancer. (1999) (12)
- Abstract OT3-2-07: Phase I study of ARN-810, a novel selective estrogen receptor degrader, in post-menopausal women with locally advanced or metastatic estrogen receptor positive breast cancer (2013) (12)
- Phase lb combination trial of a MEK inhibitor, pimasertib (MSC1936369B), and a PI3K/mTOR inhibitor, SAR245409, in patients with locally advanced or metastatic solid tumors. (2012) (11)
- The Relationship of Cetuximab-Induced Rash and Survival in Patients with Head and Neck Cancer Treated with Radiotherapy and Cetuximab (2005) (11)
- Abstract LB-174: Translation of preclinical predictive sensitivity of Ewing sarcoma to PARP inhibition: Phase II study of olaparib in adult patients with recurrent/metastatic Ewing sarcoma following failure of prior chemotherapy. (2013) (11)
- 42O_PRASSESSMENT OF GENETIC ALTERATIONS IN POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER FROM THE BOLERO-2 TRIAL BY NEXT-GENERATION SEQUENCING (2013) (11)
- Phase I, open-label study of olaparib plus cisplatin in patients with advanced solid tumors. (2012) (11)
- Abstract PD5-01: HERA trial: 10 years follow up of trastuzumab after adjuvant chemotherapy in HER2 positive early breast cancer – Final analysis (2016) (11)
- Abstract P2-16-14: Preliminary safety, pharmacokinetics and anti-tumor activity of BYL719, an alpha-specific PI3K inhibitor in combination with fulvestrant: Results from a phase I study (2013) (11)
- Phase II study of semisynthetic paclitaxel in metastatic breast cancer. (1997) (11)
- Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial (2018) (11)
- AZD5363, a catalytic pan-Akt inhibitor, in Akt1 E17K mutation positive advanced solid tumors (2015) (11)
- 451PDPHASE I STUDY OF THE PI3Kα INHIBITOR BYL719, AS A SINGLE AGENT IN PATIENTS WITH ADVANCED SOLID TUMORS (AST). (2014) (11)
- Immunohistochemical analysis of estrogen receptor in breast cancer with ESR1 mutations detected by hybrid capture-based next-generation sequencing (2018) (11)
- Abstract PD5-1: Results from the phase 2 trial of ridaforolimus, dalotuzumab, and exemestane compared to ridaforolimus and exemestane in advanced breast cancer (2015) (10)
- PI3K pathway (PI3Kp) dysregulation and response to pan-PI3K/AKT/mTOR/dual PI3K-mTOR inhibitors (PI3Kpi) in metastatic breast cancer (MBC) patients (pts). (2012) (10)
- Memorial Sloan-Kettering Cancer Center experience with paclitaxel in the treatment of breast cancer. (1995) (10)
- PIK 3 CA Genotype and a PIK 3 CA Mutation-Related Gene Signature and Response to Everolimus and Letrozole in Estrogen Receptor Positive Breast Cancer (2012) (10)
- The future of breast cancer research in danger. (2002) (10)
- Does epidermal growth factor receptor status predict activity of cetuximab in colorectal cancer patients? (2005) (10)
- A phase 1 study of LJM716 in patients with esophageal squamous cell carcinoma, head and neck cancer, or HER2-overexpressing metastatic breast or gastric cancer. (2014) (10)
- Correlation of PIK3CA mutation with pathological complete response in primary HER2-positive breast cancer: Combined analysis of 967 patients from three prospective clinical trials. (2015) (10)
- Lack of increased cardiac toxicity with sequential doxorubicin and paclitaxel. (1998) (10)
- 216 POSTER A phase I dose-escalation study of the safety, pharmacokinetics and pharmacodynamics of XL765, a novel inhibitor of PI3K and mTOR, administered orally to patients with solid tumors (2008) (10)
- 440 Superiority of tandem high-dose (HDC) over conventionally-dosed chemotherapy(CDC) in patients (Pts) with metastatic breast cancer (MBC): Updated results of the international randomised breast cancer dose-intensity study (IBDIS) (2003) (10)
- Abstract P5-18-01: Pertuzumab (P) in combination with trastuzumab (T) and docetaxel (D) in elderly patients with HER2-positive metastatic breast cancer in the CLEOPATRA study (2012) (10)
- Safety and efficacy of the selective FGFR inhibitor debio 1347 in phase I study patients with FGFR genomically activated advanced biliary tract cancer (BTC). (2018) (10)
- Health-related quality of life (HRQL) in women with HER2-overexpressing metastatic breast cancer (MBC) in a phase III study of Herceptin (R) plus chemotherapy versus chemotherapy alone (1999) (10)
- The EGF receptor family as targets for breast cancer therapy (2000) (10)
- Efficacy of vemurafenib in patients (pts) with non-small cell lung cancer (NSCLC) with BRAFV600 mutation. (2017) (10)
- Study CTKI258A2202: A multicenter, open-label phase II trial of dovitinib (TKI258) in FGFR1-amplified and nonamplified HER2-negative metastatic breast cancer. (2010) (9)
- The perspective and role of the medical oncologist in cancer prevention: a position paper by the European Society for Medical Oncology. (2008) (9)
- Trastuzumab re-treatment following adjuvant trastuzumab and the importance of distant disease-free interval: the HERA trial experience (2015) (9)
- Gemcitabine and capecitabine in previously anthracycline-treated metastatic breast cancer: a multicenter phase II study (SOLTI 0301 trial). (2010) (9)
- Evaluation of tolerability and anti-tumor activity of GDC-0032, a PI3K inhibitor with enhanced activity against PIK3CA mutant tumors, administered-to patients with advanced solid tumors (2013) (9)
- Abstract P2-16-01: Overall Survival Data from SOLTI-0701: A Multinational, Double-Blind, Placebo-Controlled, Randomized Phase 2b Study Evaluating the Oral Combination of Sorafenib and Capecitabine in Patients with Locally Advanced or Metastatic HER2-Negative Breast Cancer (2010) (9)
- A review of EGFR targeted therapy. (2003) (9)
- Author Correction: HER kinase inhibition in patients with HER2- and HER3-mutant cancers (2019) (9)
- SOLTI NeoPARP: A phase II, randomized study of two schedules of iniparib plus paclitaxel and paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer (TNBC). (2012) (9)
- Abstract P5-19-04: A phase I/II study of neratinib plus temsirolimus in HER2+ metastatic breast cancer reveals ongoing HER2 pathway dependence in many patients despite several lines of HER2 targeted therapy (2015) (9)
- Corrections to “Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab” (2019) (9)
- Breast cancer, locally advanced and metastatic (2012) (9)
- Phase II pharmacodynamic trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients previously treated with platinum-based chemotherapy: FISH results. (2005) (9)
- Efficacy, safety and tolerability of dual monoclonal antibody therapy with pertuzumab + trastuzumab in HER2+ metastatic breast cancer patients previously treated with trastuzumab. (2009) (8)
- P124 neo-ALTTO (neoadjuvant lapatinib and/or trastuzumab treatment optimisation) study [BIG 1-06/SOLTI/EGF106903]: a phase III translational study for Her2-overexpressing early breast cancer (BC) (2007) (8)
- Pharmacokinetic and exploratory exposure–response analysis of pertuzumab in patients with operable HER2-positive early breast cancer in the APHINITY study (2019) (8)
- Abstract LB-327: Loss of PTEN leads to clinical resistance to the PI3Kα inhibitor BYL719 and provides evidence of convergent evolution under selective therapeutic pressure (2014) (8)
- Corrigendum The hVps 34-SGK 3 pathway alleviates sustained PI 3 K / Akt inhibition by stimulating mTORC 1 and tumour growth (2016) (8)
- Multigene assays to improve assessment of recurrence risk and benefit from chemotherapy in early-stage colon cancer: has the time finally arrived, or are we still stage locked? (2010) (8)
- Abstract A165: mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling. (2011) (8)
- SANDPIPER: Phase III study of the PI3-kinase (PI3K) inhibitor taselisib (GDC-0032) plus fulvestrant in patients (pts) with oestrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer (BC) enriched for pts with PIK3CA-mutant tumours (2016) (8)
- OA 14.05 Phase 2 Basket Trial of Ado-Trastuzumab Emtansine in Patients with HER2 Mutant or Amplified Lung Cancers (2017) (8)
- Association between adaptive immune signature and outcome in HER2-positive breast cancer treated with trastuzumab and lapatinib in the NCCTG-N9831 (Alliance) and NeoALTTO trials. (2018) (8)
- Incidence, management, and resolution of noninfectious pneumonitis in BOLERO-2. (2013) (8)
- Performance of a high-intensity 508-gene circulating-tumor DNA (ctDNA) assay in patients with metastatic breast, lung, and prostate cancer. (2017) (8)
- Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer (2021) (8)
- Survival outcomes of the NeoALTTO study: Updated results of a randomized multicenter phase III neoadjuvant trial. (2017) (8)
- Cell Line–Specific Network Models of ER+ Breast Cancer Identify Potential PI3Kα Inhibitor Resistance Mechanisms and Drug Combinations (2021) (8)
- A Phase II Trial of Cabozantinib in Hormone Receptor‐Positive Breast Cancer with Bone Metastases (2020) (8)
- University of Dundee PDK 1-SGK 1 signaling sustains AKT-independent mTORC 1 activation and confers resistance to PI 3 K inhibition (2016) (8)
- Abstract CT044: MONARCH 1: Final overall survival analysis of a phase 2 study of abemaciclib, a CDK4 and CDK6 inhibitor, as monotherapy, in patients with HR+/HER2- breast cancer, after chemotherapy for advanced disease (2017) (8)
- Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of the selective aurora A kinase (AAK) inhibitor MLN8054 in patients (pts) with advanced solid tumors. (2016) (8)
- 218 POSTER A phase I dose-escalation study of the safety, pharmacokinetics and pharmacodynamics of XL147, a novel PI3K inhibitor administered orally to patients with advanced solid tumors (2008) (7)
- Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D). (2021) (7)
- Abstract 4564: Assessment of genetic alterations using next-generation sequencing in postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the BOLERO-2 phase III trial. (2013) (7)
- EMILIA: A phase III, randomized, multicenter study of trastuzumab-DM1 (T-DM1) compared with lapatinib (L) plus capecitabine (X) in patients with HER2-positive locally advanced or metastatic breast cancer (MBC) and previously treated with a trastuzumab-based regimen. (2011) (7)
- Abstract LB-146: A phase II randomized placebo-controlled study of AZD8931, an inhibitor of EGFR, HER2, and HER3 signaling, plus paclitaxel (P) vs P alone in patients (pts) with low HER2-expressing advanced breast cancer (BC) (THYME). (2013) (7)
- Pharmacodynamic endpoints in primary breast cancer. (2007) (7)
- Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER 2-positive metastatic breast cancer (2014) (7)
- Phase II trial of gallium nitrate in previously treated patients with small cell lung cancer (1993) (7)
- Effects of everolimus (EVE) on disease progression in bone and bone markers (BMs) in patients (pts) with bone metastases (mets). (2012) (7)
- High prevalence of BRCA1/2 germline mutations in female breast cancer patients with triple-negative phenotype (TNBC) and family history. (2010) (7)
- P3-16-01: Safety Profile and Clinical Activity of Single-Agent BKM120, a Pan-Class I PI3K Inhibitor, for the Treatment of Patients with Metastatic Breast Carcinoma. (2011) (7)
- Hormone-receptor status and likelihood of predicting pathological complete response (pCR) in the NOAH trial of neoadjuvant trastuzumab in patients (pts) with HER2-positive locally advanced breast cancer (LABC) (2008) (7)
- Validation of target engagement using 18F-fluoroestradiol PET in patients undergoing therapy with selective estrogen receptor degrader, ARN-810 (GDC-0810) (2015) (7)
- PAM50 intrinsic subtyping and pathologic responses to neoadjuvant trastuzumab-based chemotherapy in HER2-positive breast cancer. (2011) (7)
- Abstract PD3-06: Neratinib + fulvestrant for HER2-mutant, HR-positive, metastatic breast cancer: Updated results from the phase 2 SUMMIT trial (2019) (7)
- Cancer Therapy : Clinical Loss of HER 2 Amplification Following Trastuzumab-Based Neoadjuvant Systemic Therapy and Survival Outcomes (2009) (7)
- Translating p53 into the clinic (2011) (6)
- The Discrepancy Between High Pathological Complete Response (PCR) Rate and Low Breast Conserving Surgery (BCS) Following Neoadjuvant Therapy: Analysis from the Neoaltto Trial (BIG 1-06) (2012) (6)
- Efficacy of trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (MBC) previously treated with pertuzumab (P). (2017) (6)
- Double PIK3CA mutations in cis enhance PI3Kα oncogene activation and sensitivity to PI3Kα inhibitors in breast cancer. (2019) (6)
- 5013 ORAL FDG-PET/CT for Early Prediction of Response to Neoadjuvant Lapatinib, Trastuzumab, and Their Combination in HER2-positive Breast Cancer Patients: the Neo-ALTTO Study Results (2011) (6)
- PD09-03: Phase I/II Study of BKM120 in Combination with Trastuzumab in Patients with HER2 Overexpressing Metastatic Breast Cancer Resistant to Trastuzumab-Containing Therapy. (2011) (6)
- Non-Infectious Pneumonitis (NIP) in Breast Cancer (BC) Patients (Pts) Treated with Everolimus (Afinitor™) Containing Therapy: Analysis of Five Studies. (2009) (6)
- Feasibility trial of high-dose 7-day continuous-infusion ifosfamide given on an outpatient basis (1997) (6)
- a Specific Epidermal Growth Factor Receptor ( EGFR ) Tyrosine Kinase Inhibitor , Induces the Formation of Inactive EGFR / HER 2 and EGFR / HER 3 Heterodimers and Prevents Heregulin Signaling in HER 2-overexpressing Breast Cancer Cells 1 (2003) (6)
- Failure to Disclose Conflict of Interest in Article Published in JAMA on Detection of Cancer-Related Genes. (2018) (6)
- Duration of Mucositis and Dysphagia following Radiotherapy (+ Cetuximab) for Locoregionally Advanced Head and Neck Cancer (2007) (6)
- Phase I pharmacokinetic profile and early clinical evaluation of the PAN-HER inhibitor BMS-599626 (2005) (6)
- Case records of the Massachusetts General Hospital. Case 16-2012. A 32-year-old woman with HER2-positive breast cancer. (2012) (6)
- Novel agents in the era of targeted therapy: what have we learned and how has our practice changed? (2008) (6)
- Correction: Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer. (2016) (6)
- Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial. (2018) (6)
- Phase I trial of daily PI3Kα inhibitor BYL719 plus letrozole (L) or exemestane (E) for patients (pts) with hormone receptor-positive (HR+) metastatic breast cancer (MBC). (2014) (6)
- Combined anti-EGFR blockade: A phase I pharmacokinetic and molecular pharmacodynamic study of Cetuximab (Erbitux (R)) and Gefitinib (Iressa (R)) in patients with advanced colorectal, head and neck and non-small cell lung cancer expressing the EGFR (2005) (6)
- BOLERO-2: Efficacy and safety of first-line everolimus plus exemestane in advanced breast cancer. (2013) (6)
- Lapatinib is active in patients with HER2-amplified breast tumors expressing p95HER2. (2009) (6)
- Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis. (2012) (6)
- 3040 POSTER Optimal dose for an every 2 week (q2w) cetuximab (C) regimen in patients (pts) with metastatic colorectal cancer (mCRC): a phase I safety, pharmacokinetics (PK) and pharmacodynamics (PD) study of weekly (q1w) and q2w schedules (2007) (6)
- Effects of trastuzumab (H) and chemotherapy on circulating HER2 extracellular domain (ECD) in patients with metastatic breast cancer (MBC) and non-small cell lung cancer (NSCLC) (2004) (6)
- Correlation of PIK3CA mutations in cell-free DNA (cfDNA) and efficacy of everolimus (EVE) in metastatic breast cancer: Results from BOLERO-2. (2016) (6)
- Efficacy and Toxicity of the Angiogenesis Inhibitor SU 5416 As a Single Agent in Patients with Advanced Renal Cell Carcinoma , Melanoma , and Soft Tissue Sarcoma 1 (2003) (6)
- Concordance between plasma-based and tissue-based next-generation sequencing in LOTUS. (2017) (6)
- Design of RESILIENCE: A phase (Ph) III trial comparing capecitabine (CAP) in combination with sorafenib (SOR) or placebo (PL) for treatment (tx) of locally advanced (adv) or metastatic HER2-negative breast cancer (BC). (2011) (5)
- Abstract CT041: Primary results from FAIRLANE (NCT02301988), a double-blind placebo (PBO)-controlled randomized phase II trial of neoadjuvant ipatasertib (IPAT) + paclitaxel (PAC) for early triple-negative breast cancer (eTNBC) (2018) (5)
- Efficacy and safety of ixabepilone plus capecitabine in elderly patients with anthracycline- and taxane-pretreated metastatic breast cancer. (2013) (5)
- A phase 2, multicenter, open-label study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2-positive, unresectable and/or metastatic breast cancer previously treated with T-DM1. (2018) (5)
- Corrections to “Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer” (2019) (5)
- Cardiac safety and antitumor activity of doxorubicin and taxol followed by weekly taxol (AT&T) when herceptin is initiated with AT or with T alone in women with HER2-positive advanced breast cancer (2001) (5)
- 2905 Genomic characterization of brain metastases and paired primary tumors reveals branched evolution and potential therapeutic targets (2015) (5)
- Abstract GS1-04: Copy number aberration analysis to predict response to neoadjuvant anti-HER2 therapy: Results from the NeoALTTO phase III trial (2018) (5)
- Multivariate analysis (MVA) of progression-free survival (PFS) in two phase IIb, multinational, double-blind, randomized, placebo (PL)-controlled trials evaluating sorafenib (SOR) plus standard chemotherapy in patients (pts) with HER2-negative locally advanced or metastatic breast cancer (BC). (2010) (5)
- Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial (2021) (5)
- BOLERO-2: Health-related quality-of-life (HRQoL) in metastatic breast cancer patients treated with everolimus and exemestane versus exemestane. (2012) (5)
- Abstract A46: Inhibition of PIK3CA with BYL719 can overcome resistance to cetuximab in squamous cell carcinoma of the head and neck (SCCHN) (2015) (5)
- Patient-reported function, health-related quality of life, and symptoms in APHINITY: pertuzumab plus trastuzumab and chemotherapy in HER2-positive early breast cancer (2021) (5)
- Patient (pt)-reported function and symptoms in APHINITY: A randomized comparison of chemotherapy (C) + trastuzumab (H) + placebo (Pla) versus C + H + pertuzumab (P) as adjuvant therapy in pts with HER2-positive early breast cancer (EBC). (2018) (5)
- Incidence and Management of Diarrhea With Adjuvant Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. (2019) (5)
- Efficacy and safety of ixabepilone plus capecitabine in elderly patients with anthracycline- and taxane-pretreated metastatic breast cancer. (2011) (5)
- Phase III trial of non-pegylated liposomal doxorubicin (M) in combination with trastuzumab (T) and paclitaxel (P) in HER2+ metastatic breast cancer (MBC). (2013) (5)
- Neratinib induces estrogen receptor function and sensitizes HER2-mutant breast cancer to anti-endocrine therapy (2016) (5)
- A phase II study of ridaforolimus (RIDA) and dalotuzumab (DALO) in estrogen receptor-positive (ER+) breast cancer. (2011) (5)
- Author Correction: Tumour lineage shapes BRCA-mediated phenotypes (2019) (5)
- D2-04: MERIT: a prospective study of putative relationships between tumour biomarkers and clinical benefit from erlotinib in advanced non-small cell lung cancer (NSCLC) (2007) (5)
- EGFr expression and clinical outcome in head and neck cancer patients treated with radiotherapy with or without cetuximab. (2006) (5)
- Safety of everolimus for women over age 65 with advanced breast cancer (BC): 12.5-month follow-up of BOLERO-2. (2012) (5)
- Abstract CT046: A phase I basket study of the PI3K inhibitor taselisib (GDC-0032) inPIK3CA-mutated locally advanced or metastatic solid tumors (2018) (5)
- Extracellular cleaved HER2 (p95) confers partial resistance to trastuzumab but not HSP90 inhibitors in models of HER2 amplified breast cancer (2007) (5)
- Clinical benefit of lapatinib-based therapy in patients with HER2-positive breast tumors expressing p95HER2. (2009) (5)
- Phase IIb double-blind, randomized, placebo-controlled trials for the efficacy and safety of sorafenib in patients (pts) with metastatic or locally advanced breast cancer (BC): Review of the Trials to Investigate the Effects of Sorafenib in BC (TIES) program. (2009) (5)
- A phase II trial of PALA+dipyridamole in patients with advanced soft-tissue sarcoma (2004) (5)
- Abstract CT061: A phase Ib study of alpelisib (BYL719) + everolimus ± exemestane in patients with advanced solid tumors or HR+/HER2-breast cancer (2016) (5)
- Abstract P6-15-07: A Dose-Escalation Study with a Special Drug Delivery System (SDS) of BEZ235, a Novel Dual PI3K/mTOR Inhibitor, in Patients with Metastatic/Advanced Solid Tumors (2010) (4)
- OT3-01-09: Phase 3 Trial Comparing Capecitabine in Combination with SorafenIb or Placebo for Treatment of Locally Advanced or Metastatic HER2−Negative Breast Cancer (RESILIENCE). (2011) (4)
- Abstract OT2-3-09: Phase III randomized study of the oral pan-PI3K inhibitor BKM120 with fulvestrant in postmenopausal women with HR+/HER2– locally advanced or metastatic breast cancer resistant to aromatase inhibitor – BELLE-2 (2012) (4)
- 1 β-catenin Confers Resistance to PI 3 K and AKT inhibitors and Subverts FOXO 3 a to Promote Metastasis in Colon Cancer (2012) (4)
- Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265P mutations. (2018) (4)
- Abstract 648: Combined PI3K and MEK inhibition in patient-derived xenografts generated from recurrent triple negative breast cancer (2011) (4)
- Abstract A050:PIK3CAmutation status in tumor tissue and ctDNA as a biomarker for PFS in patients with HR+, HER2- ABC treated with buparlisib or placebo plus fulvestrant: results from the BELLE-2 and BELLE-3 randomized studies (2018) (4)
- Abstract P1-08-42: High HER2 expression correlates with response to trastuzumab and the combination of trastuzumab and lapatinib in the NeoALTTO phase III trial (2013) (4)
- Circulating tumor DNA in HER2 amplified breast cancer: a translational research substudy of the NeoALTTO phase 3 trial (2019) (4)
- Optimizing treatment in luminal breast cancer (2012) (4)
- BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition PI 3 K Inhibition Impairs BRCA 1 / 2 Expression and Sensitizes (2012) (4)
- HTLV-III ANTIBODIES AND CHRISTMAS DISEASE (1986) (4)
- LORELEI: A Phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib (GDC-0032) versus letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative, early-stage breast cancer. (2016) (4)
- Patient-reported physical, emotional, and social functioning in advanced breast cancer: Insights from BOLERO-2. (2013) (4)
- Pharmacokinetics (PK) of Pertuzumab (P) With Trastuzumab (T) and Docetaxel (D) in HER2-Positive First-Line Metastatic Breast Cancer (MBC): Results From the Phase III Trial Cleopatra (2012) (4)
- Missing Conflict of Interest Disclosure. (2017) (4)
- Abstract PD5-3: Phase I trial: PI3Kα inhibitor BYL719 plus aromatase inhibitor (AI) for patients with hormone receptor-positive (HR+) metastatic breast cancer (MBC) (2015) (4)
- Pharmacodynamic (PD) – Pharmacokinetic (PK) Study of Ficlatuzumab(F), A Monoclonal Antibody (MAB) Directed to the Hepatocyte Growth Factor (HGF), in Patients (PTS) with Advanced Solid Tumors who have Liver Metastases (METS) (2012) (4)
- Oncologic Therapy for Solid Tumors Alters the Risk of Clonal Hematopoiesis (2018) (4)
- Copy number aberration analysis to predict response to neoadjuvant anti-HER2 therapy: Results from the NeoALTTO phase III trial (2017) (4)
- A phase 1 study of MSC-1, a humanized anti-LIF monoclonal antibody, in patients with advanced solid tumors. (2018) (4)
- 366 Phase I Dose-escalation Study of the Oral Dual MTOR/PI3K Inhibitor BEZ235, Solid Dispersion System (SDS) Sachet Formulation, in Patients with Advanced Solid Tumors (2012) (4)
- Phase I study of the novel anticancer drug PM00104 as a 24-hour IV infusion every 3 weeks (q3w) in patients (pts) with advanced solid tumors or lymphoma. (2009) (4)
- The clinical utility of ERBB2 amplification detection in breast carcinoma using a 341 gene hybrid capture-based next generation sequencing (NGS) assay: Comparison with standard immunohistochemistry (IHC) and Fluorescence In Situ Hybridization (FISH) assays. (2015) (4)
- Abstract A75: Circulating tumor cells in human breast cancer exhibit dynamic changes in epithelial and mesenchymal composition (2013) (4)
- Abstract P3-13-01: Lurbinectedin (PM01183) activity in BRCA1/2-associated or unselected metastatic breast cancer. Interim results of an ongoing phase II trial (2015) (4)
- Everolimus in combination with exemestane in the treatment of postmenopausal women with estrogen receptor-positive metastatic breast cancer who are refractory to letrozole or anastrozole: Preliminary results of the BOLERO-2 trial. (2011) (4)
- Vemurafenib in Patients with Erdheim-Chester Disease (ECD) and Langerhans Cell Histiocytosis (LCH) Harboring BRAFV600 Mutations: A Cohort of the Histology-Independent VE-Basket Study (2016) (4)
- Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-positive metastatic breast cancer after prior pertuzumab-based therapy (2016) (4)
- Abstract LB-343: Development of plasma cell-free DNA (cfDNA) assays for early cancer detection: first insights from the Circulating Cell-Free Genome Atlas Study (CCGA) (2018) (4)
- 279 POSTER MLN8054, a selective inhibitor of Aurora A kinase: final results of a phase I clinical trial (2008) (4)
- Risk of venous and arterial thromboembolic events in patients with metastatic breast cancer treated with bevacizumab: A meta-analysis. (2010) (4)
- ESMO's new strategic plan: our society's road to the future of oncology. (2008) (4)
- Safety of everolimus for women over 65 years of age with advanced breast cancer (BC): 12.5-mo follow-up of BOLERO-2. (2012) (4)
- HOXB13 May Predict Response to Neoadjuvant Letrozole in Patients with Estrogen Receptor-Positive Breast Cancer. (2009) (3)
- Feasibility of CT scan-guided Tru-Cut serial liver biopsies to evaluate pharmacodynamic endpoints in patients with liver metastasis treated with experimental drugs (2004) (3)
- Abstract CT-08: A Phase 1 study of MEHD7945A (MEHD), a first-in-class EGFR/HER3 dual action antibody, in patients (pts) with locally advanced or metastatic epithelial tumors (2012) (3)
- Phase I, dose-finding study of AZD8931, an inhibitor of ErbB1, 2, and 3 receptor signaling, in combination with paclitaxel (P). (2011) (3)
- Prognostic factors in the diagnostic work‐up of cancer patients in an internal medicine department: does age matter? (2008) (3)
- 3LBA Everolimus Added to Exemestane Reduced Bone Markers and Disease Progression in Bone in Postmenopausal Women with Advanced Breast Cancer: Updated Results From the BOLERO-2 Trial (2012) (3)
- Efficacy and Safety of Everolimus in Postmenopausal Women With Advanced Breast Cancer (BOLERO-2): Effect of Visceral Metastases and Prior Endocrine Therapy (2012) (3)
- Are we assuming too much with our statistical assumptions? Lessons learned from the ALTTO Trial. (2019) (3)
- Europe and the century of biomedical discovery and implementation. (2011) (3)
- Role of progesterone receptor status (PR) as predictive factor of pathological complete response (pCR) to neoadjuvant chemotherapy (NACT) in breast cancer (BC) patients (pts). (2010) (3)
- Curbing tobacco's toll starts with the professionals: World No Tobacco Day (2005) (3)
- A Phase I Dose Escalation and Expansion Trial of BKM120, An Oral Pan-PI3K Inhibitor, in Patients with Advanced Solid Tumors: Analysis of Pharmacodynamic Biomarker Data (2012) (3)
- FAIRLANE: A phase II randomized, double-blind, study of the Akt inhibitor ipatasertib (GDC-0068) in combination with paclitaxel as neoadjuvant treatment for early stage triple-negative breast cancer. (2015) (3)
- Abstract P1-13-01: Phase I study of ARN-810, a novel and potent oral selective estrogen receptor degrader, in postmenopausal women with metastatic estrogen receptor positive (ER+), HER2- breast cancer (2015) (3)
- Are we assuming too much with our statistical assumptions? Lessons learned from the ALTTO trial. (2019) (3)
- Clinical management and resolution of stomatitis in BOLERO-2. (2013) (3)
- LOTUS (NCT02162719): A double-blind placebo (PBO)-controlled randomized phase II trial of first-line ipatasertib (IPAT) + paclitaxel (P) for metastatic triple-negative breast cancer (TNBC). (2017) (3)
- Reply to 'The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology' by Kirova et al. (2017) (3)
- Advances in Brief Cleavage of the HER 2 Ectodomain Is a Pervanadate-activable Process That Is Inhibited by the Tissue Inhibitor of Metalloproteases-1 in Breast Cancer Cells 1 (1999) (3)
- Abstract OT1-03-09: FAIRLANE: A phase II randomized, double-blind, study of the Akt inhibitor ipatasertib (Ipat, GDC-0068) in combination with paclitaxel (Pac) as neoadjuvant treatment for early stage triple-negative breast cancer (TNBC) (2016) (3)
- Abstract OT3-1-05: Phase I, open-label study evaluating the safety and tolerability of LJM716, BYL719 and trastuzumab in patients with metastatic HER2+ breast cancer (2015) (3)
- Cyclophosphamide, methotrexate, and chronic oral tegafur modulated by folinic acid in the treatment of patients with advanced breast carcinoma (1998) (3)
- Abstract CT330: Phase I study of PI3Kα inhibitor BYL719 + aromatase inhibitor (AI) in patients (pts) with hormone receptor-positive (HR+) metastatic breast cancer (MBC) (2015) (3)
- Long-term (8 years) assessment of trastuzumab-related cardiac events in the HERA trial. (2013) (3)
- Creating a stronger front against cancer: ESMO and ECCO join forces. (2008) (3)
- PAM50 intrinsic subtype in hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) treated with exemestane (EXE) in combination with everolimus (EVE) or placebo (PBO): A correlative analysis of the phase III BOLERO-2 trial (2018) (3)
- Abstract 4774: The antitumor effects of PI3K beta inhibitors in PTEN negative prostate cancer are enhanced by inhibition of reactivated PI3K alpha signaling (2014) (3)
- Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab. (2019) (3)
- Developing an international network for breast cancer research: the BIG experience (2011) (3)
- Abstract P2-16-04: A phase 2 study of ridaforolimus (RIDA) and dalotuzumab (DALO) in estrogen receptor positive (ER+) breast cancer (2013) (3)
- Abstract P1-09-09: Efficacy and gene expression results from SOLTI1007 NEOERIBULIN phase II clinical trial in HER2-negative early breast cancer (2017) (3)
- Cardiac Safety of TGF-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Cancer Patients in a First-in-Human Dose Study (2014) (3)
- Pharmacodynamic studies of the specific oral EGFR tyrosine kinase inhibitor (EGFR-TKI) zd1839 (‘Iressa’) in skin from cancer patients participating in phase I trials: histopathological and molecular consequences of receptor inhibition (2001) (3)
- Abstract P6-17-10: Dose justification for DS-8201a, a HER2-targeted antibody-drug conjugate, for HER2-positive breast cancer: Observed clinical data and exposure-response analyses (2019) (3)
- Pooled cardiac safety analysis of patients with HER2-positive metastatic breast cancer receiving trastuzumab. (2009) (3)
- First-in-human phase I “basket” study of Debio1347 (CH5183284), a novel FGFR inhibitor, in patients with FGFR genomically activated advanced solid tumors. (2014) (3)
- Phase I Dose Escalation Study of Taselisib (GDC-0032), an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors (2017) (3)
- Abstract P5-21-32: AZD5363 in combination with fulvestrant in AKT1-mutant ER-positive metastatic breast cancer (2018) (2)
- Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors. (2019) (2)
- Corrections to "Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis". (2019) (2)
- Abstract OT1-03-14: SANDPIPER: Phase III study of the PI3-kinase inhibitor taselisib (GDC-0032) plus fulvestrant in patients with estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer enriched for patients withPIK3CA-mutant tumors (2016) (2)
- Management of hand-foot skin reaction (HFSR)/hand-foot syndrome (HFS) in SOLTI-0701: A double-blind, randomized phase IIb study comparing sorafenib (SOR) versus placebo (PL) in combination with capecitabine (CAP) in patients (pts) with advanced breast cancer (BC). (2010) (2)
- 4005 Trastuzumab-related cardiotoxicity in the elderly: which role for cardiovascular risk factors? (2009) (2)
- Optimal dose of cetuximab administered every 2 weeks (q2w): A phase I safety, pharmacokinetics (PK) and pharmacodynamics (PD) study of weekly (q1w) and q2w schedules in patients (pts) with metastatic colorectal cancer (mCRC) (2007) (2)
- 373 Lack of pharmacokinetic interaction between erlotinib, docetaxel and capecitabine in breast cancer patients (2003) (2)
- MERIT: Analysis of differential gene expression in patients (pts) with advanced non-small-cell lung cancer (NSCLC) treated with erlotinib (2008) (2)
- P5-13-01: Survival Outcome with Bevacizumab: Activation of the Phosphatidylinositol-3 Kinase (PI3K) Pathway Due to PIK3CA Mutations or PTEN Loss Makes a Difference. (2011) (2)
- Utility of Serial cfDNA NGS for Prospective Genomic Analysis of Patients on a Phase I Basket Study (2021) (2)
- The impact of cancer in Spain: consequences for cancer prevention and care. (2010) (2)
- Pertuzumab and trastuzumab: Exploratory biomarker correlations with clinical benefit in patients with metastatic HER2-positive breast cancer. (2010) (2)
- Abstract P4-14-01: Trastuzumab emtansine improves overall survival versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer: Final results from the phase 3 EMILIA study (2016) (2)
- Abstract NG03: Genomic characterization of 101 brain metastases and paired primary tumors reveals patterns of clonal evolution and selection of driver mutations (2014) (2)
- BM-07GENOMIC CHARACTERIZATION OF BRAIN METASTASES REVEALS BRANCHED EVOLUTION AND METASTASIS-SPECIFIC MUTATIONS (2014) (2)
- Design of RESILIENCE: a phase 3 trial comparing capecitabine in combination with sorafenib or placebo for treatment of locally advanced or metastatic HER2-negative breast cancer (2011) (2)
- EGFR/VEGF signalling pathway in colorectal cancer: the way we are! (2005) (2)
- Effects of trastuzumab (H) and chemotherapy on circulating HER2 extracellular domain (ECD) in patients with metastatic breast cancer (MBC) and non-small cell lung cancer (NSCLC). (2004) (2)
- Abstract P6-07-08: Androgen receptor (AR) mutations in a cohort of patients with breast cancer (BC) who have undergone tumor genomic profiling (2016) (2)
- Abstract LB-31: USP15 stabilizes the TGF-β receptor I and promotes oncogenesis through the activation of the TGF-β signal in glioblastoma (2012) (2)
- Abstract B218: Drug-drug interaction assessment of GDC-0032, a beta-sparing inhibitor of phosphoinositide 3-kinase (PI3K), using midazolam, a sensitive CYP3A4 substrate. (2013) (2)
- Trastuzumab and pertuzumab-based versus other therapy as second-line therapy in HER2-positive metastatic breast cancer: A retrospective study from single center. (2015) (2)
- Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial. (2019) (2)
- FDG-PET/CT for early prediction of response to neoadjuvant anti-HER2 therapies in HER2-positive breast cancer (BC) patients (2012) (2)
- The Efficacy of Vemurafenib in Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Preliminary Results from VE-Basket Study (2014) (2)
- Abstract 3363: Pharmacodynamic (PD) assessment of drug activity in tumor tissue from patients (pts) enrolled in a Phase I study of MEHD7945A (MEHD), a first-in-class HER3/EGFR dual action antibody, in pts with locally advanced or metastatic epithelial tumors. (2013) (2)
- 578 POSTER A potential for combining the mTOR inhibitor RAD001 (everolimus) with the ErbB2 receptor tyrosine kinase inhibitory antibody trastuzumab in breast cancer (2006) (2)
- Erratum for the research article: mTORC1 inhibition is required forsensitivity to PI3K p110a inhibitors in PIK3CA-mutant breast cancer (Science Translational Medicine DOI: 10.1126/scitranslmed.3005747) (2018) (2)
- Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis. (2019) (2)
- Failure to Accurately Disclose Conflicts of Interest in Article Published in JAMA Otolaryngology-Head & Neck Surgery. (2019) (2)
- Abstract 653: Combination of TORC1/2 and MEK kinase inhibitors in colorectal cancer models (2011) (2)
- A novel loading regimen for trastuzumab in MBC: Boost serum levels in early cycles (2005) (2)
- Molecular markers of the mTOR pathway activation in human tumors: A baseline analysis. (2004) (2)
- Concordance between independently and investigator-assessed progression-free survival in CLEOPATRA. (2012) (2)
- Abstract P5-04-11: Non-canonical, clinical ESR1 mutations promote resistance to antiestrogen therapies (2019) (2)
- Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors. (2019) (2)
- Next-Generation Assessment of Human Epithelial Growth Factor Receptor 2 (ERBB2) Amplification Status (2017) (2)
- 41 A potential for combining the rapamycin derivative RAD001 (everolimus) with the EGF/ErbB2/VEGF receptor tyrosine kinase inhibitor AEE788 in human cancer (2004) (2)
- Effect of neoadjuvant ixabepilone (ixa) on cell cycle genes and tumor-initiating cell (TIC) signature in breast cancer (BC). (2011) (2)
- Detection of BRAF mutations in urine and plasma cell-free DNA: Application to the diagnosis and management of histiocytic disorder patients. (2014) (2)
- Abstract P1-08-23: Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer (2013) (2)
- Monitoring PIK3CA mutant allele fraction (AF) in cell-free DNA (cfDNA) in metastatic breast cancer (MBC) patients treated with PI3K{alpha}-inhibitor plus letrozole (L) or exemestane (E). (2014) (2)
- Abstract P4-12-10: Safety of pertuzumab (P) with trastuzumab (T) and docetaxel (D) in patients (pts) from Asia with HER2-positive metastatic breast cancer (MBC): Results from the phase III trial CLEOPATRA (2013) (2)
- Targeting of the EGFR As a Modulator of Cancer Chemotherapy (2005) (2)
- Corrections to "PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab". (2019) (2)
- Multicentric phase II trial of gemcitabine plus capecitabine combination in the treatment of previously anthracycline(An)-treated metastatic breast cancer (MBC): SOLTI 0301 study (2007) (2)
- Corrigendum: mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer (2018) (2)
- Abstract CT225: Ado-trastuzumab emtansine forHER2amplified or HER2 overexpressed cancers: A phase II “basket” trial (2015) (2)
- Abstract P5-08-06: PI3K blockade enhances the antitumor activity of eribulin in PIK3CA-mutant eribulin-resistant tumor xenografts (2013) (2)
- LBA7DISEASE-FREE SURVIVAL (DFS) IN THE LAPATINIB ALONE ARM AND EXPANDED RESULTS OF THE PHASE III ALTTO TRIAL (BIG 2-06; NCCTG (ALLIANCE) N063D) IN THE ADJUVANT TREATMENT OF HER2-POSITIVE EARLY BREAST CANCER (EBC) (2014) (2)
- Abstract P4-07-05: PARP inhibition in breast and ovarian patient-derived tumor xenografts (PDX) harboring germline BRCA1/2 mutations unveils mechanisms of primary and acquired resistance that restore homologous recombination (HR) (2016) (1)
- Reply to S.M. Ali et al (2009) (1)
- Phase II feasibility study of paclitaxel (T) with trastuzumab (H) and lapatinib (L) for node-negative, HER2-positive breast cancer (BC). (2014) (1)
- ASSESSING THE IMPACT OF USING THE 21-GENE RECURRENCE SCORE ASSAY ON CLINICAL DECISION MAKING IN WOMEN WITH ER-POSITIVE , HER 2-NEGATIVE EARLY STAGE BREAST CANCER (2012) (1)
- Failure to Accurately Disclose Conflicts of Interest in Articles Published in JAMA Oncology. (2019) (1)
- Abstract 1726: Acquired resistance to rapamycin and mTOR kinase inhibitors is mediated by non-overlapping mutations in distinct sites in the mTOR protein (2013) (1)
- Abstract OT2-3-06: A phase II, non-randomized, multicenter, exploratory trial of single agent BKM120 in patients with triple-negative metastatic breast cancer. (2012) (1)
- Abstract NG16: DoublePIK3CAmutations incisincrease oncogenicity and sensitivity to PI3Kα inhibitors (2020) (1)
- Abstract OT1-4-01: Multicenter phase II trial of the novel compound PM01183 (P) in BRCA1/2-associated or unselected metastatic breast cancer (MBC) (2013) (1)
- Pharmacodynamic (PD) endpoints and cellular proliferation effects of NVP-BEZ235, a dual PI3K/mTOR inhibitor, in breast cancer cells and xenografts with wild-type (WT) and activating PI3K mutations (2008) (1)
- A Pilot Study of Dose-Dense Paclitaxel With Trastuzumab and Lapatinib for Node-negative HER2-Overexpressed Breast Cancer. (2016) (1)
- Abstract PD5-04: Ki67 changes and PEPI score in the LORELEI trial: A phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative early-stage breast cancer (2018) (1)
- Freedom from progression (FFP) by adding paclitaxel (T) to doxorubicin (A) followed by CMF as adjuvant or primary systemic therapy: 10-yr results of a randomized phase III European Cooperative Trial in Operable Breast Cancer (ECTO). (2013) (1)
- Abstract OT3-1-08: A phase II, randomized study of T-DM1 versus T-DM1 plus short induction with docetaxel in first line treatment for locally advanced or metastatic HER2+ breast cancer (SOLTI-1203) (2015) (1)
- Pilot trial of an implantable microdevice for In Vivo drug sensitivity testing in patients with early stage, triple negative breast cancer receiving neoadjuvant therapy. (2016) (1)
- Mutational Analysis of Clonal Hematopoiesis in Solid Tumor Patients Illustrates the Critical Role of Systemic Anti-Cancer Therapies in the Evolution of Somatic Leukemia Disease Alleles (2016) (1)
- 249PAnalysis of overall survival by tumor response in MONARCH 1, a phase 2 study of abemaciclib, a CDK4 and CDK6 inhibitor, in women with HR+/HER2- metastatic breast cancer (MBC) after chemotherapy for advanced disease (2017) (1)
- A novel vascular tumour characterized by coexisting HRAS and GNAQ activating mutations (2018) (1)
- Exploratory analysis of the effect of taselisib on downstream pathway modulation and correlation with tumor response in ER-positive/HER2-negative early-stage breast cancer from the LORELEI trial. (2019) (1)
- Supplementary Material 10 (2014) (1)
- Preliminary results of sequential dose-dense paclitaxel followed by topotecan in extensive small-cell lung cancer (SCLC): A phase II study (2000) (1)
- Abstract 675: Network modeling of drug resistance mechanisms and drug combinations in breast cancer (2019) (1)
- Prevalence of clonal hematopoiesis in patients with advanced cancer. (2016) (1)
- Pegfilgrastim induces elevation of serum CA 15-3 in breast carcinoma patients after receiving dose-dense adjuvant chemotherapy. (2006) (1)
- Abstract 949: ARID1A is a critical regulator of luminal identity and therapeutic response in estrogen receptor-positive breast cancer (2019) (1)
- Prognostic significance of PI3K pathway (PI3Kp) dysregulation in metastatic breast cancer (MBC) patients (pts). (2012) (1)
- [Datura stramonium: an old hallucinogen making a come-back?]. (1985) (1)
- Reply to a. Avan et Al. (2015) (1)
- 109P Updated Results of the Bolero-2 Phase Iii Trial Evaluating Everolimus (Eve) for Postmenopausal Women with Advanced Breast Cancer (Abc) (2012) (1)
- Lapatinib induces HER2 stabilization and enhances the antitumor activity of trastuzumab in vivo (2008) (1)
- Differential gene expression analysis and correlation with outcome in HER2-positive metastatic breast cancer treated with HER2-targeted therapy. (2010) (1)
- Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer. (2019) (1)
- 122PCell-free (cf)DNA analysis identifies PIK3CA/AKT1 mutations associated with greater PFS improvement from the addition of ipatasertib (IPAT) to paclitaxel (P) in triple-negative breast cancer (TNBC) (2017) (1)
- Study of the Selective Aurora A Kinase Inhibitor 8054 in Patients with Advanced Solid Tumors : Safety , Ther rmacokinetics , and Pharmacodynamics (2010) (1)
- Targeting PIK3CA pathway (2017) (1)
- Abstract OT1-1-01: LORELEI: A Phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib (GDC-0032) versus letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative, early stage breast cancer (2015) (1)
- Abstract C114: Clinical response to a lapatinib-based therapy of a Li-Fraumeni Syndrome patient with a novel HER2-V659E mutation. (2013) (1)
- Abstract PD1-7: Phosphatase and tensin homolog deleted from chromosome 10 (PTEN) evaluation in the NeoALTTO trial (BIG 01-06) (2013) (1)
- Abstract 22: Cyclin E amplification, a novel mechanism of resistance to trastuzumab in HER2 amplified breast cancer (2010) (1)
- Longer follow-up on clinical outcomes of weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2 overexpressing metastatic breast cancer. (2018) (1)
- Correction: HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2 (2019) (1)
- Abstract 298: Amplification of mutant ERBB2 drives resistance to the irreversible kinase inhibitor neratinib in ERBB2-mutated breast cancer patients (2016) (1)
- Abstract S3-02: Plasma microRNA levels for predicting therapeutic response to neoadjuvant treatment in HER2-positive breast cancer: Results from Neo-ALTTO (2017) (1)
- Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer: Results From BOLERO-2 (2015) (1)
- Phosphatidyl-inositol-3-kinase Alpha catalytic subunit kinase domain mutations impart a favorable prognosis on estrogen receptor positive breast cancer through a mechanism that is independent of responsiveness to endocrine treatment. (2009) (1)
- 69 AKT3 activation mediates resistance to HER2-targeted therapies in HER2-amplified breast cancer (2014) (1)
- Clinical pharmacokinetic-pharmacodynamic (PK/PD) modeling study of the novel dual PI3K/mTOR inhibitor BEZ235. (2011) (1)
- Correction: PIK3CA Genotype and a PIK3CA Mutation-Related Gene Signature and Response to Everolimus and Letrozole in Estrogen Receptor Positive Breast Cancer (2019) (1)
- Phase II study of weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer (MBC): Updated progression-free survival with overall survival result. (2015) (1)
- Genome doubling shapes the evolution and prognosis of advanced cancers (2018) (1)
- Abstract P4-21-09: Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2 positive early breast cancer (BIG 1-06) (2017) (1)
- Colon cancer-derived oncogenic EGFR G 724 S mutant (2014) (1)
- Trastuzumab in the elderly: Is it age or cardiovascular risk profile that really matters? (2016) (1)
- Abstract P2-09-27: Predictive Factors of Complete Axillary Downstaging after Neoadjuvant Chemotherapy in Breast Cancer Patients (2010) (1)
- Vemurafenib in patients with BRAFV600 mutant glioma: A cohort of the histology-independent VE-basket study. (2017) (1)
- Abstract PD5-12: Buparlisib (BUP) or placebo (PBO) plus fulvestrant (FUL) in postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC): Overall survival (OS) results from BELLE-2, a randomized, phase III (2018) (1)
- Cell-line-specific network models of ER+ breast cancer identify PI3Kα inhibitor sensitivity factors and drug combinations (2020) (1)
- Herceptin adjuvant trials — 2006 update (2006) (1)
- Abstract 4471: Combined blockade of PI3K/AKT and EGFR/HER3 enhances antitumor activity in triple negative breast cancer. (2012) (1)
- P-949 Phase II pharmacodynamic trial of erlotinib in advancednon-small cell lung cancer (NSCLC) patients previously treated with platinum-based chemotherapy (2005) (1)
- Feasibility of pegfilgrastim as haematopoietic support for dose-dense every-2-week adjuvant chemotherapy in breast cancer. (2006) (1)
- ERCC1, RRM1 and XPD mRNA expression as a predictive marker of outcome in non-small-cell lung cancer (NSCLC) patients after platinum/gemcitabine induction chemotherapy followed by surgery. (2004) (1)
- [Biologic therapy: current and future applications in oncology]. (2007) (1)
- Abstract 4477: Dual-targeting of AMPK and PI3K/mTOR in a panel of breast cancer cell lines (2010) (1)
- Evolving options and future challenges for targeted therapies in ErbB2 (HER2)-positive breast cancer (2008) (1)
- Abstract 3746: PI3K inhibition sensitizes to PARP inhibitors in patient-derived xenograft models of triple negative breast cancer (2012) (1)
- Health-Related Quality of Life (QOL) in Metastatic Breast Cancer Patients Treated With Everolimus and Exemestane Versus Exemestane Monotherapy (2012) (1)
- Abstract PD3-03: Circulating tumor DNA in HER2 amplified breast cancer: A translational research substudy of the NeoALTTO phase 3 trial (2018) (1)
- Abstract P1-13-07: Incidence and management of diarrhea with adjuvant pertuzumab and trastuzumab in HER2-Positive breast cancer (2018) (1)
- Combined Blockade of PI3K/AKT and EGFR/HER3 Enhances Anti-Tumor Activity in Triple Negative Breast Cancer (2012) (1)
- Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy (2014) (1)
- Whole exome sequencing of pre-treatment biopsies from the neoALTTO trial to identify DNA aberrations associated with response to HER2-targeted therapies (2015) (1)
- Phase II study of sequential dose-dense paclitaxel followed by topotecan in extensive small-cell lung cancer (SCLC) (2001) (1)
- 2820 Association of p16 status and feeding tube use in patients with locoregionally advanced squamous cell cancer of the head and neck treated with radiotherapy +/- cetuximab in a phase III study (2015) (1)
- Surgical aspect in NOAH Phase III trial (neoadjuvant trastuzumab in HER2-positive locally advanced breast cancer) (2008) (1)
- Risk of gastrointestinal perforation in patients with metastatic breast cancer treated with bevacizumab: A meta-analysis. (2010) (1)
- Abstract 3596: Biomarkers of response to CDK4/6 inhibitor (CDK4/6i) in hormone receptor (HR) positive and HER2-positive breast cancer (BC) patient-derived xenografts (PDX) (2018) (1)
- Phase I study of high-dose bi-weekly gemcitabine at a constant rate infusion (CRI) without growth factor support in advanced solid tumors, including prior standard gemcitabine treated patients (2005) (1)
- Abstract 3439: FOXA1 mutations reveal distinct chromatin profiles and influence therapeutic response in breast cancer (2020) (1)
- OT3-01-16: A Phase 2 Study of Ridaforolimus (RIDA) and Dalotuzumab (DALO) in Estrogen Receptor Positive (ER+) Breast Cancer. (2011) (1)
- 387 A phase I study of AEE788, a novel multi-targeted inhibitor of ErbB and VEGF receptor family tyrosine kinases (2004) (1)
- 238 Reversal of primary and acquired PARP-inhibitor resistance in BRCA-mutated triple-negative breast cancers by inhibition of transcriptional cyclin-dependent kinases (CDKs) (2014) (1)
- 346 EGFR therapies in other tumour types (2003) (1)
- Abstract 1101: Functional genomics of HER2 and HER3 mutations and response to neratinib (2015) (1)
- Abstract P6-12-01: Phase II study of taselisib (GDC-0032) plus fulvestrant in HER2-negative, hormone receptor-positive advanced breast cancer: Analysis byPIK3CAandESR1mutation status from circulating tumor DNA (2017) (1)
- Phase II evaluation of the efficacy and safety of trastuzumab plus pertuzumab therapy in patients with HER2-positive metastatic breast cancer that had progressed during trastuzumab treatment (2008) (1)
- Human pharmacokinetic (PK) characterization of the novel dual-action anti-HER3/EGFR antibody MEHD7945A (MEHD) in patients with refractory/recurrent epithelial tumors. (2012) (1)
- EGF Receptor Inhibition by Antibody as Anticancer Therapy (1997) (1)
- Colon cancer-derived oncogenic EGFR G724S mutant identified by whole genome sequence analysis is dependent on asymmetric dimerization and sensitive to cetuximab (2014) (1)
- S43 Review of new targeted drugs: Crawling towards the adjuvant setting (2009) (1)
- [Sarcoma of soft tissue]. (1991) (0)
- 7184 Docetaxel activity in second line treatment for urothelial carcinoma: a retrospective analysis (2009) (0)
- Abstract 781: Modeling the impact of somatic alterations across human cancers (2016) (0)
- Abstract P4-12-01: Molecular features and survival outcomes of the intrinsic subtypes of breast cancer based on HER2 gene amplification (2013) (0)
- Breast Cancer Therapy Annual (2002) (0)
- Prognostic significance of elevated pretreatment serum CA-125 in patients (pts) with epithelial ovarian cancer (CEO) treated with surgery and platinum/taxane-based chemotherapy (2008) (0)
- Serial next generation sequencing (NGS) of cell free DNA (cfDNA) and clonal evolution of AKT1 E17K mutant tumors: Analyses from patients (pts) enrolled on a phase I basket study of an AKT inhibitor (AZD5363). (2016) (0)
- Abstract 924: Predictive biomarker identification for combined anti-mTOR and anti-IGF-1R treatment in luminal B breast cancer (2014) (0)
- Results From the Phase III Trial CLEOPATRA Asia With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Safety Profile of Pertuzumab With Trastuzumab and Docetaxel in Patients From (2014) (0)
- PI3K blockade reverses primary resistance and adaptation to eribulin in PI3K-pathway activated breast cancer tumors (2016) (0)
- Clinical benefit of lapatinib-based therapy in patients with HER2-positive breast tumors expressing p95HER2 (2009) (0)
- Abstract 3917: DoublePIK3CAmutations incisenhance oncogene activation and sensitivity to PI3K alpha inhibitors in breast cancer (2019) (0)
- Abstract PR06: Overcoming resistance to PI3K inhibitors in breast cancer: Results of a pooled shRNA screen and combinatorial drug screen (2013) (0)
- Lessons from a positive randomized trial of high-dose chemotherapy in metastatic breast cancer: learn from our mistakes, build on our successes, drain the bathwater, hold the baby (2004) (0)
- PG 5.03 Targeting PIK3CA pathway (2015) (0)
- Abstract 4509: Clinical genomic profiling of 1000 metastatic breast cancer patients: actionable targets, novel alterations, and clinical correlations (2016) (0)
- Tumor-specific PI3K inhibition by targeted delivery in head and neck squamous cell carcinoma (2016) (0)
- 804 Dual MTORC1/2 and HER2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-HER2 Therapy (2012) (0)
- Abstract P4-21-34: Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-Positive metastatic breast cancer after prior pertuzumab-based therapy (2017) (0)
- 5BA Identification of gene expression profiles that predict response to HER2-targeted therapy (2009) (0)
- S26 Novel Biological Therapeutic Targets (2005) (0)
- Abstract 2107: PDK1 blockade overcomes intrinsic resistance to PI3Kα inhibition (2016) (0)
- Efficacy and gene expression results from SOLTI1007, a phase II study evaluating neoadjuvant eribulin in hormone receptor (HR)-positive/HER2-negative breast cancer (2016) (0)
- Identification of CDK4/6-response biomarkers using estrogen receptor-positive breast cancer patient-derived xenografts (PDX) (2016) (0)
- Abstract 4891: Gene expression analysis of paired baseline (BL) and on-treatment tumor samples from FAIRLANE, a double-blind placebo (PBO)-controlled randomized phase II trial of neoadjuvant ipatasertib (IPAT) plus paclitaxel (PAC) in early triple-negative breast cancer (eTNBC) (2019) (0)
- Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane. (2012) (0)
- Targeting Breast Cancer with Care. Meeting (2004) (0)
- Erratum: RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer (Journal of Clinical Investigation (2013) 123:6 (2551-2563) DOI:10.1172/JCI66343) (2014) (0)
- Abstract 915: Expanded biomarker results from a phase I dose escalation study of GDC-0032, a beta isoform-sparing PI3K inhibitor (2014) (0)
- Abstract 4690: Inhibition of PI3K-AKT signaling causes a FOXO-dependent induction of receptor tyrosine kinase expression and phosphorylation in cancer (2011) (0)
- Abstract 4078: KRAS mutation status is associated with stromal inactivation in colorectal cancer and predicts poor response to neoadjuvant chemoradiotherapy (2016) (0)
- The ECCO–ESMO Collaboration – A Powerful Force in Combating Cancer (2008) (0)
- Abstract 4881: Molecular screening of patients with FGFR alterations for phase 1 (ph1) study with the selective FGFR inhibitor Debio 1347 (2019) (0)
- Managing Cancer: Leading oncologist Josep Baselga offers his prescription for dealing with cancer (2011) (0)
- 27th HUGO-IABCR Congress 2010: Oral Presentation Abstracts, 5–7 October 2010, Singapore (2010) (0)
- Emerging molecular therapies in breast cancer. (2009) (0)
- Abstract P6-18-30: Phase Ib/II study of capecitabine 7/7 schedule with neratinib in patients with HER2-positive metastatic breast cancer (MBC) (2019) (0)
- HER kinase inhibition in patients with HER2- and HER3-mutant cancers (2018) (0)
- Anti-tumor activity of the Hsp90 inhibitor IPI-504 in HER2 positive trastuzumab-resistant breast cancer. (2011) (0)
- Abstract P5-21-05: Withdrawn (2018) (0)
- Abstract OT2-6-13: A randomized phase 2 study of the triplet combination of ridaforolimus (RIDA), dalotuzumab (DALO) and exemestane (EX) compared to the ridaforolimus, exemestane doublet in high proliferation, estrogen receptor positive (ER+) advanced breast cancer (2013) (0)
- 417 A Mechanistic Logic for Dual Targeting of HER2 and PI3K/AKT/mTOR Signaling in HER2 Amplified Breast Cancer (2012) (0)
- Lack of RAD51 foci formation enables the identification of PARP inhibitor sensitive breast tumors (2016) (0)
- on Well Established A 431 Cell Xenografts-Diamminedichloroplatinum cis Monoclonal Antibodies plus Antitumor Effect of Anti-Epidermal Growth Factor Receptor (2007) (0)
- Abstract 2321: Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS signaling. (2013) (0)
- Next-Generation Sequencing of Matched Normal Blood Identifies Clonal Hematopoiesis in a Significant Subset of Solid Tumor Patients without Hematologic Malignancies (2015) (0)
- 244 Development of xenoimplants from germline BRCA1/2 mutant breast cancer (BC) for the identification of predictive biomarkers, mechanisms of resistance against poly(ADP-ribose) polymerase (PARP) inhibitors and evaluation of novel therapies (2014) (0)
- Abstract P2-09-07: Low levels of HER2 extracellular domain (ECD) compared to intracelluar domain (ICD) in NeoALTTO may segregate benefit from lapatinib and trastuzumab in breast cancer (2018) (0)
- Abstract 2446: Real-time molecular imaging of targeted therapies in patient-derived tumor cells by quantitative immunofluorescence microscopy (2012) (0)
- LYNPARZA ® ( olaparib ) First-Line Maintenance Therapy Nearly Doubled the Time Without Disease Progression or Death in Phase 3 POLO Trial for Patients with Germline BRCA-Mutated Metastatic Pancreatic Cancer Release (2019) (0)
- Phase II study of gemcitabine (G), trastuzumab (H), and pertuzumab (P) for HER2-positive metastatic breast cancer (MBC) after prior pertuzumab-based therapy. (2017) (0)
- Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer (2022) (0)
- University of Dundee The hVPS 34-SGK 3 pathway counteracts inhibition of the PI 3 K-Akt to maintain mTORC 1 and tumour growth (2016) (0)
- New Targeted Agents in Luminal BC (2012) (0)
- Antitumor Activity of Dual PI3K and ER Blockade in ER Positive Breast Cancer Models (2012) (0)
- TERT Hotspot Promoter Mutations and TERT Gene Amplification in Phyllodes Tumors of the Breast (2016) (0)
- Abstract B106: mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer. (2013) (0)
- Abstract P1-19-05: Capivasertib (AZD5363) in combination with fulvestrant in PTEN-mutant ER+ metastatic breast cancer (2020) (0)
- Alpelisib (BYL719) plus Fulvestrant in PIK3CA-altered and PIK3CA wild-type ER+ advanced breast cancer. An open-label, phase 1b dose-escalation and expansion study (2018) (0)
- Effect of body mass index (BMI) on response to neoadjuvant therapy in human epidermal growth factor receptor 2 (HER2) positive breast cancer (BC): Analysis from NeoALLTO trial (2016) (0)
- [P2-09-01] T-cell receptor beta chain variable region (TRBV) expression patterns predict response to combined trastuzumab/lapatinib treatment in the NeoALTTO/BIG-1-06 trial (2018) (0)
- Session C: Molecular Oncology, Diagnostics and Pharmacology C1 A NOVEL CANDIDATE GENE IN HUMAN ENDOMETRIAL CANCER AT CHROMOSOME 10Q26 IN AND OF PATIENTS WITH NON-SMALL-CELL LUNG CANCER (NSCLC) (EGFR) INHIBITOR GEFITINIB AND THE MAMMALIAN TARGET OF RAPAMYCIN (MTOR) INHIBITOR EVEROLIMUS (2004) (0)
- 160 INVITED Biopsy-driven biomarker development: pharmacodynamic studies in early clinical trials (2007) (0)
- Correction: Management of breast cancer with targeted therapies: importance of heterogenicity (2010) (0)
- [Value of the electrophysiologic study of the diaphragm in the diagnosis of phrenic paralysis]. (1985) (0)
- Abstract B38: p90RSK mediates resistance to PI3K-pathway inhibitors in breast cancer (2015) (0)
- Pharmacodynamic S tudies o f t he E pidermal G rowth F actor Receptor I nhibitor Z D1839 i n S kin F rom C ancer P atients: Histopathologic a nd M olecular C onsequences o f Receptor I nhibition (2002) (0)
- Longer follow-up on cardiac safety and distant disease free survival of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab in patients with early-stage HER2-positive breast cancer. (2017) (0)
- Abstract P2-05-04: Deregulation of A-to-I RNA editing is associated with poor prognosis in HER2+ breast cancers in the neoALTTO trial (2017) (0)
- Activity of ixabepilone and PARP inhibitors in triple-negative breast cancer (TNBC) based on gene expression. (2010) (0)
- Abstract 2964: On-treatment changes in circulating tumor DNA (ctDNA) level as an early predictor of clinical outcome in the LOTUS randomized phase 2 trial of 1st-line ipatasertib (IPAT) + paclitaxel (PAC) for metastatic triple-negative breast cancer (mTNBC) (2018) (0)
- Effect of lapatinib on accumulation of inactive HER2 at the cell membrane and on antibody-dependent cellular cytotoxicity (ADCC) mediated by trastuzumab: A novel mechanism for the enhanced effects of combined anti-HER2 therapy (2008) (0)
- Therapeutic Bene fi t of Selective Inhibition of p110 a PI3-Kinase in Pancreatic Neuroendocrine Tumors (2016) (0)
- [HTLV III infection and study of lymphocyte populations in 184 hemophiliacs]. (1987) (0)
- Safety of Herceptin monotherapy administered on a 3-weekly schedule: Preliminary data from a phase II study in women with HER2-positive metastatic breast cancer (2002) (0)
- Autoimmunity and Benefit from Trastuzumab Treatment in Breast Cancer: Results from the HERA Trial (2019) (0)
- ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer (2020) (0)
- [Emphysematous cholecystitis: early diagnosis by echography]. (1985) (0)
- Abstract A21: Compound PIK3CA mutations support a mutational dose-response model for oncogene activation and response to PI3K inhibitor targeted therapy in breast cancer (2020) (0)
- Abstract 683: Evaluation of PTEN and PIK3CA status in breast cancer for patient selection: Cross-validation between institutions (2012) (0)
- Phase I evaluation of the PI3 kinase (PI3K) inhibitor taselisib (GDC-0032) in multiple locally advanced or metastatic PIK3CA mutant solid tumor types. (2016) (0)
- Dual inhibition of HER2 in breast cancer treatment (2012) (0)
- Abstract 927: Genomic profiling of metastatic breast cancer identifies the Hippo pathway to be a key determinant of CDK4/6 inhibitor sensitivity (2019) (0)
- Abstract PL07-01: Molecular profiling of breast cancer in Mexico: Identification of novel therapeutic targets through whole genome sequencing analysis. (2012) (0)
- 5064 POSTER Breast Cancer Subtype and Survival in Metastatic Patients Treated With Bevacizumab (2011) (0)
- Abstract C23: Phase 3 trial comparing capecitabine in combination with sorafenib or placebo for treatment of locally advanced or metastatic HER2-negative breast cancer (RESILIENCE). (2011) (0)
- Abstract P4-13-20: Activity of HP-based therapies as third and later lines for the treatment of HER2-positive metastatic breast cancer: A retrospective study from a single institution (2016) (0)
- Prognostic implications of phosphatidylinositol 3-kinase (PI3K) pathway alterations in metastatic triple-negative breast cancer (mTNBC). (2011) (0)
- 1. Bogner L, Hartmann M, Rickhney M and Zdenek M. Application of an inverse kernel concept to Monte Carlo based IMRT. Med Phys 2006; 33, Nr. 12: 4749-4757 (ISSN 0094-2405 - IF 2,305). (2006) (0)
- Therapeutic Strategies TARGETED THERAPIES IN BREAST CANCER (2013) (0)
- Oncogenesis and Colon Exhibit Distinct Patterns of Genome Instability and Gastrointestinal Adenocarcinomas of the Esophagus, Stomach, (2012) (0)
- Cancer Therapy : Clinical Biomarkers Predict p 53 Gene Therapy Efficacy in Recurrent Squamous Cell Carcinoma of the Head and Neck (2009) (0)
- GDC-0032, A Novel p110α Inhibitor, Specifically Radiosensitizes Head and Neck Squamous Cell Carcinomas Harboring Activating PIK3CA Alterations (2014) (0)
- Abstract B144: NVP‐BEZ235, a dual inhibitor of PI3K and mTOR, induces MAPK phosphorylation in HER2‐positive cells (2009) (0)
- Abstract 639: Measuring PI3K and MAPK pathways inhibition, comparison between conventional IHC and AQUA-TMA technology (2010) (0)
- 158PDAdjuvant anti-HER2 therapy, treatment-induced amenorrhea (TIA) and survival in premenopausal patients (pts) with HER2-positive (HER2+) early breast cancer (EBC): Analysis from the ALTTO trial (BIG 2-06) (2017) (0)
- 4012 Adjuvant docetaxel and cyclofosfamide in breast cancer patients over 65 years: compliance and toxicity (2009) (0)
- BOLERO-2: Everolimus in combination with exemestane in the treatment of postmenopausal women with estrogen receptor-positive ADVANCED breast cancer refractory to letrozole or anastrozole (2011) (0)
- Efficacy of vinorelbine plus trastuzumab (VT) in patients (pts) with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab (T). (2010) (0)
- 184 INVITED The pros and cons of signal transduction inhibitors in breast cancer (2007) (0)
- Abstract 2640: Clonal hematopoiesis identified by matched-normal blood sequencing of solid tumor patients without hematologic malignancy is common and is associated with decreased overall survival (2016) (0)
- Effective incorporation of biospecimen collection for translational studies into a phase III trial: The NeoALTTO experience (BIG 01-06) (2013) (0)
- 359 Tumor Pharmacodynamic Assessments by Reverse Phase Protein Array Reveal Broad Pathway Inhibition in Patients Treated with an AKT Kinase Inhibitor (2012) (0)
- Phase II study of gemcitabine (G), trastuzumab (H), and pertuzumab (P) for HER2-Positive metastatic breast cancer (MBC) after prior HP- or TDM/P-based therapy. (2016) (0)
- Next generation sequencing (NGS) in lung adenocarcinoma (LA) as a guide to treatment selection. (2016) (0)
- 71 Novel regulation of estrogen receptor transcription by the PI3K pathway (2014) (0)
- Evaluation of overall survival (OS) in patients (pts) with metastatic breast cancer (MBC) according to phosphathidylinositol-3-kinase (PI3K) pathway status. (2011) (0)
- Is Next Generation Sequencing (NGS) Ready for Routine Clinical Practice in Gliomas? Results of a Prospective Study Utilizing the MSK-IMPACT Assay (2015) (0)
- Identification of a molecular signature of radiographic response to cetuximab in patients (pts) with advanced colorectal cancer (2005) (0)
- Abstract P5-18-02: Selective Crossover in Randomized Trials of Adjuvant Trastuzumab for Breast Cancer: Coping with Success (2012) (0)
- Interpretation of renal and urinary system diseases: clinical utility of general examination of urine. (2010) (0)
- Supplementary Material 8 (2013) (0)
- Cardiac safety of 3-weekly herceptin monotherapy (2003) (0)
- Human Teratocarcinomas and Retinoic Acid-Mediated Tumor Differentiation (2020) (0)
- 133 INVITED Approaches to targeted therapy optimization: The Epidermal Growth Factor Receptor Family as a model system (2007) (0)
- SOLTI (Solid Tumor Intensification) Group experience with high-dose chemotherapy treatment for early breast carcinoma (2005) (0)
- Tumour lineage shapes BRCA-mediated phenotypes (2019) (0)
- Abstract P1-07-19: Mass Spectrometry Based Quantitative Analysis of the HER Family receptors in FFPE Breast Cancer Tissue (2012) (0)
- Circulating Tumor DNA in HER2-Ampli fi ed Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial (2019) (0)
- Abstract P2-09-03: Identifying clinically relevant subgroups of women with HER2-positive breast cancer: An analysis of Neo-ALTTO using the 41-gene TRAR score (2018) (0)
- Abstract P1-08-09: EGFR expression is associated with decreased response from HER2 targeted therapeutics in the neo-adjuvant setting in the NeoALTTO trial (2013) (0)
- 75 Loss of PTEN leads to acquired resistance to the PI3Ka inhibitor BYL719: a case of convergent evolution under selective therapeutic pressure (2014) (0)
- Neoadjuvant chemoradiotherapy (CT-RT) in patients (pts) with stage II-IVA esophageal cancer (EC): Retrospective analysis of a Spanish single institution (2008) (0)
- Adjuvant Letrozole and Zoledronic Acid In Postmenopausal Hormone Receptor – Positive Early Breast Cancer : ZO-FAST , 5-Year Follow-Up (2012) (0)
- Elkabets-Mutant Breast Cancer PIK 3 CA Inhibitors in α mTORC 1 Inhibition Is Required for Sensitivity to PI 3 K p 110 (2013) (0)
- 1 INVITED Targeted therapies (2006) (0)
- Status o f E pidermal G rowth F actor R eceptor A ntagonists i n the B iology a nd T reatment o f C ancer (2003) (0)
- Targeting the HER Family of Receptors in the Treatment of Advanced Breast Cancer (2006) (0)
- The legacy of Thomas Tursz: building a leading comprehensive cancer center in Europe. (2018) (0)
- Abstract 1811: Antitumor activity of lapatinib in combination with the dual mTORC1/2 inhibitor INK-128 in breast tumors resistant to anti-HER2 therapy (2012) (0)
- Abstract 4122: Tumor-specific PI3K inhibition via nanoparticle targeted delivery in head and neck squamous cell carcinoma (2017) (0)
- Abstract C32: First‐in‐human clinical, pharmacokinetic (PK) and pharmacodynamic (PD) phase I study of the first‐in‐class spliceosome inhibitor E7107 administered IV (bolus) on days 1, 8, and 15 every 28 days to patients with solid tumors (2009) (0)
- 627 PI3K- and ERK-pathway biomarker comparison by IHC, IF/AQUA™ and RPPA upon AKT inhibition (2010) (0)
- Confounding effects of clonal hematopoiesis in clinical genomic profiling of solid tumors. (2018) (0)
- 257 Design of RESILIENCE: a Phase 3 TRial Comparing CapecitabinE in Combination with SorafenIb or PLacebo for Treatment of Locally Advanced or MetastatIc HER2-Negative Breast CancEr (2012) (0)
- The interpretation of kidney and urinary system diseases. (2009) (0)
- RESULTS Genomic Features of Advanced , Post-Treatment Breast Cancer (2019) (0)
- Puma Biotechnology Announces Publication of Abstracts on Neratinib for the AACR Annual Meeting 2017 (2019) (0)
- 367 Emerging pharmacokinetic (PK)-pharmacodynamic (PD) profile of AEE788, a novel multi-targeted inhibitor of ErbB and VEGF receptor family tyrosine kinases (2004) (0)
- Abstract 4727: Genomic characterization of brain metastases reveals divergent evolution and metastasis specific mutations (2015) (0)
- Abstract 3129: Patient-derived tumor xenografts (PDXs) recapitulate the antitumor activity of novel therapies in metastatic breast cancer (MBC) patients (pts) (2017) (0)
- Interpretation of the diseases of renal and urinary systems. (2010) (0)
- 531 Evaluation of PTEN and PIK3Ca Status in Breast Cancer for Patient Selection – Cross-validation Between Institutions (2012) (0)
- 30 INVITED Combination of monoclonal antibodies and Tyrosine Kinase Inhibitors with the same target (2006) (0)
- BOLERO-2: Everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone receptor-positive breast cancer. (2012) (0)
- Abstract C174: RAF kinase dimerization mediates clinical acquired resistance to RAF/EGFR inhibition in BRAF V600E colorectal cancer (2015) (0)
- Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer (2021) (0)
- Abstract P3-03-01: DoublePIK3CAmutations incisdrive oncogene addiction and enhance sensitivity to PI3K alpha inhibitors in breast cancer (2020) (0)
- Abstract P5-17-01: A definition of a high-risk early-breast cancer population based on data from the collaborative trials in neoadjuvant breast cancer (CTNeoBC) meta-analysis (2013) (0)
- A RB-1 loss of function gene-signature (RBsig) as a tool to predict response to neoadjuvant chemotherapy (CT) plus anti-HER2 agents (H): A substudy of the NeoALTTO trial (BIG 1-06). (2018) (0)
- Medical Oncology, The Medical Oncology Centre of Rosebank, Johannesburg, (2014) (0)
- Low cardiotoxicity of nonpegylated liposomal doxorubicin (NPLD) in patients (pts) with metastatic breast cancer (MBC) previously exposed to 360 mg/m2 of doxorubicin (D). (2010) (0)
- Timing of re-excision surgery (S2) for positive margins (PM) and initiation of adjuvant systemic treatment (aRx) in early breast cancer patients (BC pts). (2010) (0)
- Next generation sequencing (NGS) in resectable non-small cell lung cancer (NSCLC): Therapeutic implications. (2016) (0)
- Cancer screening practices (CSP) among women at risk of hereditary breast and ovarian cancer syndrome (HBOS) before genetic testing in Spain (2008) (0)
- Curvature Analysis of Estrogen Receptor Positive Breast Cancer Under PI3K Inhibition (2016) (0)
- 605 Quantitative analyses of the impact of Akt inhibitor GDC-0068 on cell signaling and implications for clinical pharmacodynamic assessments (2010) (0)
- P1-17-09: A Phase 1/2 Dose-Escalation Study of SAR245408 (S08) or SAR245409 (S09) in Combination with Letrozole (L) in Subjects with Hormone Receptor-Positive and HER2−Negative (HR+/HER2−) Breast Cancer (BC) Refractory to a Nonsteroidal Aromatase Inhibitor (AI). (2011) (0)
- First-in-human clinical, pharmacokinetic (PK), and pharmacodynamic (PD) phase I study of the first-in-class spliceosome inhibitor E7107 administered IV (bolus) on days 1, 8, and 15 every 28 days to patients with solid tumors. (2016) (0)
- Neoadjuvant chemotherapy with HER2 inhibitors for breast cancer – Authors' reply (2012) (0)
- Challenges in assessing overexpression (2004) (0)
- Corrections to "Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors". (2019) (0)
- Tumor mutational load predicts survival after immunotherapy across multiple cancer types (2019) (0)
- Correction: 18F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials (2019) (0)
- Abstract P2-01-14: circulating tumor cells in breast cancer exhibit dynamic changes in epithelial and mesenchymal cell composition (2012) (0)
- Abstract P4-08-02: Reactivation of oncogenic signaling through mTOR inhibitors-induced feedback adaptations. (2012) (0)
- Abstract 1288: A Phase I evaluation of safety, pharmacokinetics (PK) and pharmacodynamics (PD) of LDE225, a smoothened (Smo) antagonist, in patients with advanced solid tumors (2011) (0)
- Abstract B02: Co-clinical trial of olaparib in breast and ovarian patient-derived tumor xenografts (PDX) enables the identification of response biomarkers (2016) (0)
- Abstract P4-07-04: PARP1/2 inhibition in a subset of triple negative breast cancer (TNBC) patient-derived tumor xenografts (PDX) identifies predictive biomarkers of response (2016) (0)
- Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms (2015) (0)
- Abstract 150: Identification of determinants of sensitivity to AKT inhibition using breast cancer (BC) patient-derived tumor xenografts (PDX) (2017) (0)
- Anti-HER2 monoclonal antibodies (2001) (0)
- 12 Everolimus Added to Exemestane Reduced Bone Markers in Postmenopausal Women with Advanced Breast Cancer (ABC): the BOLERO-2 Trial (2012) (0)
- Abstract P2-09-20: Biomarker analysis of the LOTUS trial of first-line ipatasertib (IPAT) + paclitaxel (PAC) in metastatic triple-negative breast cancer (TNBC) (2018) (0)
- Abstract 5703: Oncologic therapy shapes the fitness landscape of clonal hematopoiesis (2020) (0)
- Abstract 1752: BRCA-mediated tumorigenesis is origin and cell-type dependent (2019) (0)
- Abstract 999: ESR1 mutations activate and confer hormone resistance via distinct mechanisms (2017) (0)
- Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial. (2016) (0)
- Abstract P6-01-04: Breast ultrasound and mammography and response to neoadjuvant lapatinib, trastuzumab and their combination in HER2 positive breast cancer: Results from Neo-ALTTO (BIG 1-06) (2016) (0)
- Author Correction: Tumour lineage shapes BRCA-mediated phenotypes (2019) (0)
- Cover Nature Medicine 2012 (2015) (0)
- Evaluation of PTEN and PIK3CA Status in Breast Cancer for Patient Selection (2012) (0)
- 21 Rational combination therapies (2010) (0)
- Abstract LB-292: p95HER2-T cell bispecific antibody for breast cancer treatment (2018) (0)
- Expression levels of ERBB2, ESR1, immune and proliferation signatures measured by RNASeq predict response to anti-HER2 treatment in the neoALTTO trial. (2015) (0)
- Abstract 4452: p90RSK mediates resistance to PI3K-pathway inhibitors in breast cancer. (2013) (0)
- Abstract 2399: Circulating tumor DNA (ctDNA) analysis of PIK3CA and AKT1 mutations in patients enrolled onto the Phase 1b study of the PI3K inhibitor taselisib (GDC-0032) in solid malignancies (2015) (0)
- Effect of dose-intensive chemotherapy on quality of life (2005) (0)
- Abstract P3-07-66: Efficacy and gene expression results from eribulin SOLTI1007 neoadjuvant study (2016) (0)
- José Baselga: A Vision and Roadmap for Cancer Research. (2016) (0)
- Receptor targeted therapies (2004) (0)
- Pregnancies during and following trastuzumab (T) and/or lapatinib (L) in patients (pts) with HER2-positive (HER2+) early breast cancer (EBC): Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials. (2018) (0)
- Abstract 4346: PI3K pathway mediated splicing defects in ER+ breast cancers (2019) (0)
- Clinical risk factors as predictors of potential cardiotoxicity related to nonpegylated liposomal doxorubicin (NPLD) in metastatic breast cancer (MBC) patients (pts) previously treated with conventional anthracyclines (A). (2011) (0)
- Abstract P4-01-03: Withdrawn (2019) (0)
- Abstract 2825: Identification of CDK4/6-response biomarkers using estrogen receptor-positive breast cancer patient-derived xenografts (PDX) (2016) (0)
- P3-14-27: Pegylated Liposomal Doxorubicin (PLD) as Primary Treatment in Estrogen Receptor (ER) and HER2 Poor Breast Cancer and Risk of Developing Cardiotoxicity or Elderly Patients (pt). Results from the Phase II CAPRICE Study. (2011) (0)
- Abstract P1-07-09: Serum activin A and outcomes in HR+ /HER2- metastatic breast cancer patients treated with everolimus: Results from BOLERO-2 (2018) (0)
- Biological targets in breast cancer therapeutics (2003) (0)
- AND EGF RECEPTOR BLOCKADE (1996) (0)
- Abstract 962: Multiplexed mutational profiling of breast tumor as an efficient clinical tool for personalized breast cancer treatment (2012) (0)
- Abstract 375: Oncologist use and perception of large panel next generation tumor sequencing (2017) (0)
- A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer (2017) (0)
- Abstract LB-20: mTOR kinase inhibition relieves feedback suppression of receptor tyrosine kinase leading to a biphasic regulation of AKT signaling in breast cancer cells (2012) (0)
- Abstract P6-14-02: A Phase 3 Randomized, Controlled Trial of Myocet, Trastuzumab and Paclitaxel vs. Trastuzumab and Paclitaxel for 1st Line Therapy of HER2+ Metastatic Breast Cancer (2010) (0)
- Tenbaum et al. Nature Med 2012 Supp Mat (2015) (0)
- A virtual consult service to optimize clinical trial participation in patients with metastatic breast cancer. (2014) (0)
- Autoimmunity and benefit from trastuzumab treatment in breast cancer: Results from the HERA phase III trial. (2018) (0)
- MET activation drives resistance to cetuximab in head and neck cancer (2018) (0)
- Next-Generation Assessment of ERBB2 (HumanEpidermal Growth Factor Receptor 2) Amplification Status (2016) (0)
- Cutaneous rash as a surrogate marker of time to tumor progression (TTP) with erlotinib in previously treated advanced non- small cell lung cancer (NSCLC) (2008) (0)
- Employing multiplex immunofluorescence to quantify Her2 and phosphorylated Her2 in formalin-fixed, paraffin-embedded breast tumor specimens (2009) (0)
- Interpretation of diseases of renal and urinary systems (II). (2010) (0)
- Edinburgh Research Explorer PIK3CA Genotype and a PIK3CA Mutation-Related Gene Signature and Response to Everolimus and Letrozole in Estrogen Receptor Positive Breast Cancer (2018) (0)
- Abstract B169: Neratinib has clinical activity in HER2-amplified breast cancer patients with tumors that have acquired activating mutations in HER2 (2018) (0)
- Cancer Discovery at one year: the editors' interim analysis. (2012) (0)
- Abstract P1-14-17: Pathologic complete response rate with doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-positive early stage breast cancer: A single institution experience (2016) (0)
- Abstract LB-96: Sensitivity to combined MEK and mTORC1/2 inhibition in colorectal cancer is dictated by p53 mutational status. . (2013) (0)
- Combination Therapy with Cisplatinum and EGF Receptor Blockade (1996) (0)
- 18 The Neo BIG programme (2010) (0)
- Abstract NG01: Blockade of EGFR and HER3 enhances PI3K/Akt antitumor activity in triple negative breast cancer (2014) (0)
- 337 Biomarkers in early clinical development (2010) (0)
- Abstract P2-08-19: Exploratory biomarker analyses of FAIRLANE, a double-blind placebo (PBO)-controlled randomized phase II trial of neoadjuvant ipatasertib (IPAT) + paclitaxel (PAC) for early triple-negative breast cancer (TNBC) (2019) (0)
- TGF-β1, pSMAD and TGFβ-related markers in Patients with advanced metastatic cancer (2006) (0)
- 31 INVITED Using biomarkers in phase II studies (2008) (0)
- Author response: The tumor suppressor PTEN and the PDK1 kinase regulate formation of the columnar neural epithelium (2015) (0)
This paper list is powered by the following services:
Other Resources About José Baselga
What Schools Are Affiliated With José Baselga?
José Baselga is affiliated with the following schools:
- University of Oxford
- University of Valencia
- Seoul National University
- Université libre de Bruxelles
- Washington University in St. Louis
- University of Oviedo
- McGill University
- Yale University
- Osaka Metropolitan University
- Complutense University of Madrid
- University of Edinburgh
- Paracelsus Medical University
- Kindai University
- Heidelberg University
- Prince of Songkla University
- Medical University of Vienna
- University of Ulm
- Indiana University
- MD Anderson Cancer Center
- University of Sydney
- Cornell University
- University of Siena
- Massachusetts General Hospital
- Tampere University
- Indiana University Bloomington
- Autonomous University of Barcelona
- National Cheng Kung University
- Rockefeller University
- University of North Carolina at Chapel Hill
- University of Barcelona
- Autonomous University of Madrid
- Harvard University
